<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0109200145
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Birato
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ABIRATERONE ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3696.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Natco Pharma Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Natco Pharma Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2096]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Boston Oncology Arabia
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BX03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BIRATO contains a medicine called abiraterone acetate. It is used to treat prostate cancer in adult men that has spread to other parts of the body. BIRATO stops your body from making testosterone; this can slow the growth of prostate cancer.</p><p>When BIRATO is prescribed for the early stage of disease where it is still responding to hormone therapy, it is used with a treatment that lowers testosterone (androgen deprivation therapy).</p><p>When you take this medicine your doctor will also prescribe another medicine called prednisone or prednisolone. This is to lower your chances of getting high blood pressure, having too much water in your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take BIRATO</strong></p><p>- &nbsp;if you are allergic to abiraterone acetate or any of the other ingredients of this medicine (listed&nbsp;in section 6).</p><p>- &nbsp;if you are a woman, especially if pregnant. BIRATO is for use in male patients only.</p><p>- &nbsp;if you have severe liver damage.</p><p>- &nbsp;in combination with Ra-223 (which is used to treat prostate cancer).</p><p>Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking this medicine: - if you have liver problems</p><p>- &nbsp;if you have been told you have high blood pressure or heart failure or low blood potassium (low</p><p>blood potassium may increase the risk of heart rhythm problems)</p><p>- &nbsp;if you have had other heart or blood vessel problems</p><p>- &nbsp;if you have an irregular or rapid heart rate</p><p>- &nbsp;if you have shortness of breath</p><p>- &nbsp;if you have gained weight rapidly</p><p>- &nbsp;if you have swelling in the feet, ankles, or legs</p><p>- &nbsp;if you have taken a medicine known as ketoconazole in the past for prostate cancer</p><p>- &nbsp;about the need to take this medicine with prednisone or prednisolone</p><p>- &nbsp;about possible effects on your bones</p><p>- &nbsp;if you have high blood sugar.</p><p>&nbsp;</p><p>Tell your doctor if you have been told you have any heart or blood vessel conditions, including heart rhythm problems (arrhythmia), or are being treated with medicines for these conditions.</p><p>Tell your doctor if you have yellowing of the skin or eyes, darkening of the urine, or severe nausea or vomiting, as these could be signs or symptoms of liver problems. Rarely, failure of the liver to function (called acute liver failure) may occur, which can lead to death.</p><p>Decrease in red blood cells, reduced sex drive (libido), muscle weakness and/or muscle pain may occur.</p><p>BIRATO must not be given in combination with Ra-223 due to a possible increase in the risk of bone fracture or death.</p><p>If you plan to take Ra-223 following treatment with BIRATO and prednisone/prednisolone, you must wait 5 days before starting treatment with Ra-223.</p><p>If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p><strong><u>Blood monitoring</u></strong></p><p>BIRATO may affect your liver, and you may not have any symptoms. When you are taking this medicine, your doctor will check your blood periodically to look for any effects on your liver.</p><p><u><strong>Children and adolescents</strong></u></p><p>This medicine is not for use in children and adolescents. If BIRATO is accidentally ingested by a child or adolescent, go to the hospital immediately and take the package leaflet with you to show to the emergency doctor.</p><p><u><strong>Other medicines and BIRATO</strong></u></p><p>Ask your doctor or pharmacist for advice before taking any medicine.<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is important because BIRATO may increase the effects of a number of medicines including heart medicines, tranquilisers, herbal medicines (e.g., St John&rsquo;s wort) and others. Your doctor may want to change the dose of these medicines. Also, some medicines may increase or decrease the effects of BIRATO. This may lead to side effects or to BIRATO not working as well as it should.</p><p>Androgen deprivation treatment may increase the risk of heart rhythm problems. Tell your doctor if you are receiving medicine<br />- Used to treat heart rhythm problems (e.g. quinidine, procainamide, amiodarone and sotalol);<br />- Known to increase the risk of heart rhythm problems [e.g. methadone (used for pain relief and</p><p>part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics (used for serious mental illnesses)].</p><p>Tell your doctor if you are taking any of the medicines listed above.</p><p><u><strong>BIRATO with food</strong></u></p><p>- This medicine must not be taken with food (see section 3, &ldquo;Taking this medicine&rdquo;). - Taking BIRATO with food may cause side effects.</p><p><u><strong>Pregnancy and breast-feeding</strong></u></p><p>BIRATO is not for use in women.<br />- This medicine may cause harm to the unborn child if it is taken by women who are pregnant.<br />- If you are having sex with a woman who can become pregnant, use a condom and another&nbsp;effective birth control method.<br />- If you are having sex with a pregnant woman, use a condom to protect the unborn child.</p><p><u><strong>Driving and using machines</strong></u></p><p>This medicine is not likely to affect your being able to drive and use any tools or machines.</p><p><u><strong>BIRATO contains lactose and sodium</strong></u></p><p>- BIRATO contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>- This medicine also contains approximately 27 mg of sodium in a two tablet daily dose. To be taken into consideration by patients on a controlled sodium diet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>How much to take</strong></p><p>The recommended dose is 1,000 mg (four&nbsp;tablets) once a day.</p><p><strong>Taking this medicine</strong></p><p>- Take this medicine by mouth.<br />- Do not take BIRATO with food.<br />- Take BIRATO at least one hour before or at least two hours after eating (see section 2, &ldquo;BIRATO&nbsp;with food&rdquo;).<br />- Swallow the tablets whole with water.<br />- Do not break the tablets.<br />- BIRATO is taken with a medicine called prednisone or prednisolone. Take the prednisone or</p><p>prednisolone exactly as your doctor has told you.<br />- You need to take prednisone or prednisolone every day while you are taking BIRATO.<br />- The amount of prednisone or prednisolone you take may need to change if you have a medical&nbsp;emergency.<br />Your doctor will tell you if you need to change the amount of prednisone or prednisolone you take. Do not stop taking prednisone or prednisolone unless your doctor tells you to.</p><p>Your doctor may also prescribe other medicines while you are taking BIRATO and prednisone or prednisolone.</p><p><strong>If you take more BIRATO than you should</strong></p><p>If you take more than you should, talk to your doctor or go to a hospital immediately.</p><p><strong>If you forget to take BIRATO</strong></p><p>- If you forget to take BIRATO or prednisone or prednisolone, take your usual dose the following day.</p><p>- If you forget to take BIRATO or prednisone or prednisolone for more than one day, talk to your doctor without delay.</p><p><strong>If you stop taking BIRATO</strong></p><p>Do not stop taking BIRATO or prednisone or prednisolone unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Stop taking BIRATO and see a doctor immediately if you notice any of the following:</strong></p><p>- Muscle weakness, muscle twitches or a pounding heart beat (palpitations). These may be signs that the level of potassium in your blood is low.</p><p>Other side effects include:<br /><strong>Very common</strong>&nbsp;(may affect more than 1 in 10 people):<br />Fluid in your legs or feet, low blood potassium, liver function test increases, high blood pressure, urinary tract infection, diarrhoea.</p><p><strong>Common</strong>&nbsp;(may affect up to 1 in 10 people):<br />High fat levels in your blood, chest pain, irregular heart beat (atrial fibrillation), heart failure, rapid heart rate, severe infections called sepsis, bone fractures, indigestion, blood in urine, rash.</p><p><strong>Uncommon</strong>&nbsp;(may affect up to 1 in 100 people):<br />Adrenal gland problems (related to salt and water problems), abnormal heart rhythm (arrhythmia), muscle weakness and/or muscle pain.</p><p><strong>Rare</strong>&nbsp;(may affect up to 1 in 1,000 people):<br />Lung irritation (also called allergic alveolitis).<br />Failure of the liver to function (also called acute liver failure).</p><p><strong>Not known&nbsp;</strong>(frequency cannot be estimated from the available data): Heart attack, changes in ECG - electrocardiogram (QT prolongation).</p><p>Bone loss may occur in men treated for prostate cancer. BIRATO in combination with prednisone or prednisolone may increase bone loss.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep this medicine out of the sight and reach of children.<br />- Do not use this medicine after the expiry date which is stated on the carton, cardboard wallet,&nbsp;and the blister.<br />&nbsp;&nbsp;The expiry date refers to the last day of that month.<br />- This medicinal product does not require any special storage conditions.<br />- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist&nbsp;how to throw away medicines you no longer use.<br />These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is abiraterone acetate. Each uncoated tablet contains 250 mg abiraterone&nbsp;acetate.<br />- The other ingredients are lactose monohydrate; microcrystalline cellulose; croscarmellose&nbsp;sodium; povidone K 30; sodium lauryl sulfate; colloidal silicon dioxide and magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BIRATO tablets are white to off-white, oval shaped tablets, debossed with “ABR” on one side and “250" on other side.
120 tablets of BIRATO are packed in HDPE container and closed with CR closure with induction sealing wad.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tadawi Biomedical Company,</p><p>Sudair Industrial Zone,</p><p>Sudair,</p><p>Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 07/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي&nbsp;<strong>بيراتو</strong>&nbsp;على دواء يُسمى أسيتات أبيراتيرون. ويُستخدم لعلاج سرطان البروستات لدى الرجال البالغين الذين انتشر عندهم إلى أجزاء أخرى من الجسم. يمنع&nbsp;<strong>بيراتو&nbsp;</strong>جسمك من صنع التستوستيرون, وهذا يمكن أن يُبطِّئ نمو سرطان البروستات.</p><p dir="RTL">عندما يوصف&nbsp;<strong>بيراتو</strong>&nbsp;لمرحلة مبكرة من المرض حيث لا يزال يستجيب للعلاج الهرموني، يتم استخدامه مع علاج يُخفض التستوستيرون (علاج فقدان الأندروجين).</p><p dir="RTL">عندما تأخذ هذا الدواء، سوف يصف لك طبيبك أيضاً دواءً آخر يُسمى بريدنيزون أو بريدنيزولون. وهذا يقلل من فرص إصابتك بضغط الدم المرتفع، أو وجود كمية كبيرة من الماء في جسمك (احتباس سوائل)، أو خفض مستويات مادة كيميائية تعرف باسم البوتاسيوم في دمك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تأخذ بيراتو</strong></p><p dir="RTL">- إذا كان لديك حساسية من أسيتات أبيراتيرون أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">- إذا كنتِ امرأةً، وخاصة إذا كنتِ حاملاً. إن دواء&nbsp;<strong>بيراتو&nbsp;</strong>خاص للاستخدام لدى المرضى الذكور فقط.</p><p dir="RTL">- إذا كان لديك تلف حاد في الكبد.</p><p dir="RTL">- بالمشاركة مع&nbsp;Ra-223&nbsp;(الذي يُستخدم لعلاج سرطان البروستات).</p><p dir="RTL">لا تأخذ هذا الدواء إذا كان أيّاً مما سبق ينطبق عليك. إذا كنت غير متأكد, تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء:</p><p dir="RTL">- إذا كان لديك مشاكل في الكبد.</p><p dir="RTL">- إذا تم إخبارك بأن لديك ارتفاع ضغط دم أو قصور قلب أو انخفاض بوتاسيوم الدم (انخفاض بوتاسيوم الدم ربما يزيد من خطورة مشاكل ضربات نظم القلب).</p><p dir="RTL">- إذا كنت تعاني من مشاكل قلبية أو أوعية دموية أخرى.</p><p dir="RTL">- إذا كان لديك معدل ضربات قلب غير منتظم أو سريع.</p><p dir="RTL">- إذا كان لديك ضيق في التنفس.</p><p dir="RTL">- إذا اكتسبت وزناً بسرعة.</p><p dir="RTL">- إذا كان لديك تورُّم في القدمين, الكاحلين, أو الساقين.</p><p dir="RTL">- إذا أخذت سابقاً دواءً يُعرف باسم كيتوكونازول لعلاج سرطان البروستات.</p><p dir="RTL">- عن حاجتك لأخذ هذا الدواء مع بريدنيزون أو بريدنيزولون.</p><p dir="RTL">- عن التأثيرات الجانبية المحتملة على عظامكَ.</p><p dir="RTL">- إذا كان لديك سكر دم مرتفع.</p><p dir="RTL">أخبر طبيبك إذا تم إخبارك أن لديك أية حالات قلبية أو وعائية دموية، بما في ذلك مشاكل نظم القلب (عدم انتظام ضربات القلب)، أو أنك سبق أن عولجتَ بأدوية لهذه الحالات.</p><p dir="RTL">أخبر طبيبك إذا كان لديك اصفرار في الجلد أو العينين، سواد في البول، أو غثيان شديد أو قيء، حيث أنها قد تكون علامات أو أعراض لمشاكل في الكبد. نادراً, ما قد يحدث قصور في وظائف الكبد (يُسمى فشل الكبد الحاد)، مما قد يؤدي إلى الوفاة.</p><p dir="RTL">قد يحدث انخفاض في خلايا الدم الحمراء، انخفاض في الإثارة الجنسية (الشهوة الجنسية)، ضعف العضلات و/أو ألم في العضلات.</p><p dir="RTL">يجب عدم إعطاء&nbsp;<strong>بيراتو</strong>&nbsp;بالمشاركة مع&nbsp;Ra-223&nbsp;بسبب احتمال زيادة خطر الإصابة بكسور في العظام أو الوفاة.</p><p dir="RTL">إذا كنت تخطط لتناول&nbsp;Ra-223&nbsp;بعد المعالجة بدواء&nbsp;<strong>بيراتو&nbsp;</strong>وبريدنيزون أو بريدنيزولون, يجب عليك الانتظار 5 أيام قبل بدء المعالجة بدواء&nbsp;Ra-223.</p><p dir="RTL">إذا لم تكن متأكداً فيما إذا كان ما سبق ينطبق عليك، تحدث إلى طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مراقبة الدم</strong></p><p dir="RTL">قد يؤثر&nbsp;<strong>بيراتو</strong>&nbsp;على كبدك، وقد لا تظهر لديك أية أعراض. عندما تتناول هذا الدواء، سيقوم طبيبك بفحص دمك بشكل دوري لينظر فيما إذا كان يوجد أية تأثيرات على الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">هذا الدواء ليس للاستخدام لدى الأطفال والمراهقين. إذا تم بلع&nbsp;<strong>بيراتو</strong>&nbsp;خطأً من قبل طفل أو مراهق، انقله إلى المستشفى فوراً واصطحب معك نشرة العبوة ليراها طبيب الإسعاف.</p><p dir="RTL"><strong>الأدوية الأخرى و بيراتو</strong></p><p dir="RTL">اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو قد تناولت مؤخراً أو قد تتناول أية أدوية أخرى. وهذا أمر هام لأن&nbsp;<strong>بيراتو</strong>&nbsp;قد يزيد من تأثيرات عدد من الأدوية بما فيها أدوية القلب, المهدئات, والأدوية العشبية (مثل نبتة القديس جون) وغيرها. قد يرغب طبيبك في تغيير جرعة هذه الأدوية. أيضاً، بعض الأدوية قد تزيد أو تقلل من تأثيرات&nbsp;<strong>بيراتو</strong>. وقد يؤدي هذا إلى تأثيرات جانبية أو عدم عمل&nbsp;<strong>بيراتو&nbsp;</strong>كما ينبغي.</p><p dir="RTL">معالجة فقدان الأندروجين قد تزيد من خطر حدوث مشاكل في ضربات نظم القلب. أخبر طبيبك إذا كنت تتلقى دواء:</p><p dir="RTL">- يُستخدم لعلاج مشاكل نظم القلب (مثل كينيدين, بروكائيناميد, أميودارون وسوتالول)؛</p><p dir="RTL">- إذا كنتَ على علمٍ بزيادة خطر حدوث مشاكل في ضربات نظم القلب [مثال ميثادون (المُستخدم لتخفيف الآلام وقسم من سموم الإدمان على المخدرات)، موكسيفلوكساسين (مضاد حيوي)، مضادات الذهان (المُستخدمة في الأمراض العقلية الخطيرة)].</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ أيّاً من الأدوية المذكورة أعلاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>بيراتو مع الطعام</strong></p><p dir="RTL">- يجب عدم تناول هذا الدواء مع الطعام (انظر القسم 3، &quot;كيف تأخذ بيراتو&quot;).</p><p dir="RTL">- إن تناول&nbsp;<strong>بيراتو</strong>&nbsp;مع الطعام قد يسبب تأثيرات جانبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">دواء&nbsp;<strong>بيراتو</strong>&nbsp;ليس للاستخدام لدى النساء.</p><p dir="RTL">- قد يسبب هذا الدواء ضرراً على الجنين إذا تناولته النساء الحوامل.</p><p dir="RTL">- إذا كنت تمارس الجنس مع امرأة يمكن أن تصبح حاملاً، استخدم واقي ذكري وطريقة فعالة أخرى لمنع الحمل.</p><p dir="RTL">- إذا كنت تمارس الجنس مع امرأة حامل، استخدم واقي ذكري لحماية الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر هذا الدواء على قدرتك على القيادة واستخدام أية أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي بيراتو على لاكتوز وصوديوم</strong></p><p dir="RTL">- يحتوي&nbsp;<strong>بيراتو</strong>&nbsp;على لاكتوز (نوع من السكر). فإذا أخبرك طبيبك بأنك لا تتحمل بعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء.</p><p dir="RTL">- يحتوي هذا الدواء أيضاً حوالي 27 ملغ من الصوديوم في جرعة يومية من قرصين. يجب أخذ ذلك بالاعتبار من قبل المرضى الذين يتبعون نظاماً غذائياً لمراقبة الصوديوم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائماً تماماً كما أخبرك طبيبك. وتأكد مع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الكمية التي تأخذها</strong></p><p dir="RTL">الجرعة الموصى بها هي 1000 ملغ (قرصان) مرة واحدة في اليوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل هذا الدواء</strong></p><p dir="RTL">- تناول هذا الدواء عن طريق الفم.</p><p dir="RTL">- لا تأخذ&nbsp;<strong>بيراتو&nbsp;</strong>مع الطعام.</p><p dir="RTL">- تناول&nbsp;<strong>بيراتو</strong>&nbsp;قبل ساعة على الأقل أو بعد ساعتين على الأقل من تناول الطعام (انظر القسم 2، &quot;بيراتو مع الطعام&quot;).</p><p dir="RTL">- ابتلع الأقراص كلها مع الماء.</p><p dir="RTL">- لا تكسر الاقراص.</p><p dir="RTL">- يؤخذ&nbsp;<strong>بيراتو</strong>&nbsp;مع دواء يسمى بريدنيزون أو بريدنيزولون. خذ بريدنيزون أو بريدنيزولون تماماً كما أخبرك طبيبك.</p><p dir="RTL">- تحتاج إلى تناول بريدنيزون أو بريدنيزولون كل يوم أثناء تناولك&nbsp;<strong>بيراتو.</strong></p><p dir="RTL">- قد تحتاج إلى تغيير كمية بريدنيزون أو بريدنيزولون إذا كنت تعاني من حالة صحية طارئة. سيخبرك طبيبك إذا كنت بحاجة إلى تغيير كمية بريدنيزون أو بريدنيزولون الذي تتناوله. لا توقف تناول بريدنيزون أو بريدنيزولون ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">قد يصف لك طبيبك أيضاً أدوية أخرى أثناء تناولك&nbsp;<strong>بيراتو</strong>&nbsp;مع بريدنيزون أو بريدنيزولون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا أخذت بيراتو أكثر مما يجب</strong></p><p dir="RTL">إذا أخذت أكثر مما يجب، تحدث إلى طبيبك أو اذهب إلى المستشفى فوراً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت أن تأخذ بيراتو</strong></p><p dir="RTL">- إذا نسيت أخذ&nbsp;<strong>بيراتو</strong>&nbsp;أو بريدنيزون أو بريدنيزولون، خذ الجرعة المعتادة في اليوم التالي.</p><p dir="RTL">- إذا نسيت أخذ&nbsp;<strong>بيراتو</strong>&nbsp;أو بريدنيزون أو بريدنيزولون لأكثر من يوم واحد، تحدث إلى طبيبك دون تأخير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن أخذ بيراتو</strong></p><p dir="RTL">لا تتوقف عن أخذ&nbsp;<strong>بيراتو</strong>&nbsp;أو بريدنيزون أو بريدنيزولون ما لم يخبرك طبيبك بذلك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء تأثيرات جانبية، وإن كانت لا تحدث لكل شخص.</p><p dir="RTL"><strong>توقف عن تناول بيراتو واستشر الطبيب فوراً إذا لاحظت أيّاً مما يلي:</strong></p><p dir="RTL">- ضعف العضلات، تشنجات العضلات أو ضربات قلب قوية (خفقان). قد تكون هذه علامات انخفاض مستوى البوتاسيوم في دمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثيرات جانبية أخرى تتضمن:</strong></p><p dir="RTL"><strong>شائعة جداّ&nbsp;</strong>(قد تؤثر بأكثر من 1 من كل 10 أشخاص):</p><p dir="RTL">سوائل في ساقيك أو قدميك، انخفاض بوتاسيوم الدم، زيادة في اختبار وظائف الكبد، ارتفاع ضغط الدم، التهاب المجرى البولي، إسهال.</p><p dir="RTL"><strong>شائعة</strong>&nbsp;(قد تؤثر حتى في 1 من كل 10 أشخاص):</p><p dir="RTL">ارتفاع مستويات الدهون في دمك، ألم في الصدر، ضربات قلب غير منتظمة (رجفان أذيني)، قصور قلب، معدل سريع في&nbsp;&nbsp;ضربات القلب، التهابات حادة تسمى تعفن الدم، كسور العظام، عسر هضم، دم في البول، طفح.</p><p dir="RTL"><strong>غير شائعة</strong>&nbsp;(قد تؤثر حتى في 1 من كل 100 شخص):</p><p dir="RTL">مشاكل الغدة الكظرية (تتعلق بمشاكل الملح والماء)، نظم قلب غير طبيعي (عدم انتظام ضربات القلب)، ضعف العضلات و/أو ألم العضلات.</p><p dir="RTL"><strong>نادرة</strong>&nbsp;(قد تؤثر حتى في 1 من كل 1000 شخص):</p><p dir="RTL">تهيُّج الرئة (ويسمى أيضاً التهاب الحويصلات الهوائية التحسسي).</p><p dir="RTL">فشل عمل الكبد (ويسمى أيضاً فشل الكبد الحاد).</p><p dir="RTL"><strong>غير معروفة</strong>&nbsp;(لا يمكن تقدير تكرارها من البيانات المتاحة):</p><p dir="RTL">نوبة قلبية، تغيرات في تخطيط القلب - تخطيط كهربية القلب (إطالة زمن الـ&nbsp;QT).</p><p dir="RTL">قد يحدث فقدان العظام لدى الرجال الذين يعالجون من سرطان البروستات. دواء&nbsp;<strong>بيراتو</strong>&nbsp;بالمشاركة مع بريدنيزون أو بريدنيزولون قد يزيد من فقدان العظام.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- احفظ هذا الدواء بعيداً عن رؤية ومتناول الأطفال.</p><p dir="RTL">- لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الكرتونة, وحافظة الورق المقوى, والبليستر. ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">- هذا المنتج الطبي لا يتطلب أية ظروف تخزين خاصة.</p><p dir="RTL">- لا تتخلص من أية أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. هذه التدابير سوف تُساعد على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- المادة الفعالة هي أسيتات أبيراتيرون. كل قرص غير مطلي يحتوي على 250 ملغ من أسيتات أبيراتيرون.</p><p dir="RTL">- المكونات الأخرى هي مونوهيدرات اللاكتوز؛ مايكروكريستالين سيليلوز, كروسكارميلوز الصوديوم, بوڤيدون&nbsp;K30, صوديوم لوريل سلفات, ثاني أكسيد السيليكون الغروي وستيآرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">- أقراص&nbsp;<strong>بيراتو&nbsp;</strong>بلون أبيض إلى أبيض خفيف, أقراص بيضاوية الشكل, محفور على أحد جوانبها الحروف &quot;ABR&quot; وعاى الجانب الآخر التركيز &quot;250&quot;. كل 120 قرص من&nbsp;<strong>بيراتو&nbsp;</strong>معبأة في عبوة بولي إيثيلين عالية الكثافة&nbsp;HDPE&nbsp;ومغلقة بغالقة مقاومة للأطفال&nbsp;CR&nbsp;محكمة مع ختم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة تداوي الطبية الحيوية،</p><p dir="RTL">منطقة سُدير الصناعية,</p><p dir="RTL">سُدير،</p><p dir="RTL">المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             07/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BIRATO 250 (Abiraterone Acetate Tablets USP 250 mg)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each uncoated tablet contains 250 mg of abiraterone acetate. Excipients with known effect
Product contains lactose.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
White to off-white, oval shaped tablets, debossed with “ABR” on one side and “250" on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Abiraterone&nbsp;Acetate&nbsp;is&nbsp;indicated&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone&nbsp;for:</strong></p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->the treatment of&nbsp;metastatic castration&nbsp;resistant prostate cancer (mCRPC) in&nbsp;adult men&nbsp;who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).</p><p><!--[if !supportLists]-->&middot;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->the&nbsp;treatment&nbsp;of&nbsp;mCRPC&nbsp;in&nbsp;adult men&nbsp;whose&nbsp;disease&nbsp;has&nbsp;progressed&nbsp;on&nbsp;or&nbsp;after&nbsp;a&nbsp;docetaxel- based chemotherapy regimen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This&nbsp;medicinal&nbsp;product&nbsp;should&nbsp;be&nbsp;prescribed&nbsp;by&nbsp;an&nbsp;appropriate&nbsp;healthcare&nbsp;professional.&nbsp;<u>Posology</u></p><p>The&nbsp;recommended&nbsp;dose is&nbsp;1,000 mg&nbsp;(four&nbsp;250&nbsp;mg tablets)&nbsp;as&nbsp;a&nbsp;single&nbsp;daily&nbsp;dose&nbsp;that&nbsp;must not be taken with food (see &ldquo;Method of administration&rdquo; below). Taking the tablets with food increases systemic exposure to abiraterone (see sections 4.5 and 5.2).</p><p><u>Dosage&nbsp;of&nbsp;prednisone&nbsp;or&nbsp;prednisolone</u></p><p>For mHSPC, Abiraterone Acetate is used with 5 mg prednisone or prednisolone daily. For&nbsp;mCRPC,Abiraterone&nbsp;Acetate&nbsp;is&nbsp;used&nbsp;with&nbsp;10&nbsp;mg&nbsp;prednisone&nbsp;or&nbsp;prednisolone&nbsp;daily.</p><p>Medical castration with luteinising hormone releasing hormone (LHRH) analogue should be continued during treatment in patients not surgically castrated.</p><p><u>Recommended&nbsp;monitoring</u></p><p>Serum&nbsp;transaminases should be measured prior&nbsp;to&nbsp;starting treatment, every&nbsp;two weeks for&nbsp;the first three months of treatment and monthly thereafter. Blood pressure, serum potassium and fluid retention should be monitored monthly. However, patients with a significant risk for congestive heart failure should be monitored every 2 weeks for the first three months of treatment and monthly thereafter (see section 4.4).</p><p>In patients with pre-existing hypokalaemia or those that develop hypokalaemia whilst being treated&nbsp;withAbiraterone&nbsp;Acetate,&nbsp;consider&nbsp;maintaining&nbsp;the&nbsp;patient&#39;s&nbsp;potassium&nbsp;level&nbsp;at&nbsp;&ge; 4.0&nbsp;mM.</p><p>For&nbsp;patients&nbsp;who develop&nbsp;Grade&nbsp;&ge;&nbsp;3&nbsp;toxicities&nbsp;including hypertension,&nbsp;hypokalaemia,&nbsp;oedema and other nonmineralocorticoid toxicities, treatment should be withheld and appropriate medical&nbsp;management should be instituted. Treatment with BIRATO should not be reinitiated until symptoms of the toxicity have resolved to Grade 1 or baseline.</p><p>In&nbsp;the event of&nbsp;a missed daily&nbsp;dose of&nbsp;either BIRATO,&nbsp;prednisone,&nbsp;or&nbsp;prednisolone, treatment should be resumed the following day with the usual daily dose.</p><p><u>Hepatotoxicity</u></p><p>For patients who develop hepatotoxicity during treatment (alanine aminotransferase [ALT] increases or aspartate aminotransferase [AST] increases above 5 times the upper limit of normal [ULN]), treatment should be withheld immediately (see section 4.4). Re-treatment following&nbsp;return&nbsp;of&nbsp;liver function&nbsp;tests&nbsp;to&nbsp;the&nbsp;patient&#39;s&nbsp;baseline may&nbsp;begiven&nbsp;at a&nbsp;reduced&nbsp;dose of 500 mg (one tablet) once daily. For patients being re-treated, serum transaminases should be monitored at a minimum of every two weeks for three months and monthly thereafter. If hepatotoxicity recurs at the reduced dose of 500 mg daily, treatment should be discontinued. If patients develop severe hepatotoxicity (ALT or AST 20 times the ULN) anytime while on therapy, treatment should be discontinued and patients should not be re-treated.</p><p><u>Hepatic&nbsp;impairment</u></p><p>No&nbsp;dose&nbsp;adjustment&nbsp;is&nbsp;necessary&nbsp;for&nbsp;patients&nbsp;with&nbsp;pre-existing&nbsp;mild&nbsp;hepatic&nbsp;impairment,&nbsp;Child- Pugh Class A.</p><p>Moderate hepatic impairment (Child-Pugh Class B) has been shown to increase the systemic exposure to abiraterone by approximately four-fold following single oral&nbsp;doses of&nbsp;abiraterone acetate 1,000 mg (see section 5.2). There are no data on the clinical safety and efficacy of multiple doses of abiraterone acetate when administered to patients with moderate or severe hepatic impairment (Child-Pugh&nbsp;Class&nbsp;B&nbsp;or&nbsp;C). No dose&nbsp;adjustment can&nbsp;bepredicted. The&nbsp;use of BIRATO should be cautiously assessed in patients with moderate hepatic impairment, in whom&nbsp;the&nbsp;benefit&nbsp;clearly&nbsp;should&nbsp;outweigh&nbsp;the&nbsp;possible&nbsp;risk&nbsp;(see&nbsp;sections&nbsp;4.2&nbsp;and&nbsp;5.2).&nbsp;BIRATO should not be used in patients with severe hepatic impairment (see sections 4.3, 4.4 and 5.2).</p><p><u>Renal&nbsp;impairment</u></p><p>No&nbsp;dose&nbsp;adjustment&nbsp;is&nbsp;necessary&nbsp;for&nbsp;patients&nbsp;with&nbsp;renal&nbsp;impairment&nbsp;(see&nbsp;section&nbsp;5.2).&nbsp;However, there is no clinical experience in patients with prostate cancer and severe renal impairment. Caution is advised in these patients (see section 4.4).</p><p><u>Paediatric&nbsp;population</u></p><p>There&nbsp;is&nbsp;no&nbsp;relevant&nbsp;use&nbsp;of&nbsp;BIRATO&nbsp;in&nbsp;the&nbsp;paediatric&nbsp;population.</p><p><u>Method&nbsp;of&nbsp;administration</u>&nbsp;BIRATO is for oral use.</p><p>The tablets should be taken at least one hour before or at least two hours after eating. These should be swallowed whole with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                -	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
-	Women who are or may potentially be pregnant (see section 4.6).
-	Severe hepatic impairment [Child-Pugh Class C (see sections 4.2, 4.4 and 5.2)].
-	BIRATO with prednisone or prednisolone is contraindicated in combination with Ra-223.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypertension,&nbsp;hypokalaemia,&nbsp;fluid&nbsp;retention&nbsp;and&nbsp;cardiac&nbsp;failure&nbsp;due&nbsp;to&nbsp;mineralocorticoid</u>&nbsp;<u>excess</u></p><p>BIRATO may cause hypertension, hypokalaemia, and fluid retention (see section 4.8) as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition (see section 5.1). Co-administration of a corticosteroid suppresses adrenocorticotropic hormone (ACTH) drive, resulting in a reduction in incidence and severity of these adverse reactions. Caution is required in treating patients whose underlying medical conditions might be compromised&nbsp;by&nbsp;increases&nbsp;in&nbsp;blood&nbsp;pressure,&nbsp;hypokalaemia&nbsp;(e.g.,&nbsp;those&nbsp;on&nbsp;cardiac&nbsp;glycosides), or fluid retention (e.g., those with heart failure, severe or unstable angina pectoris, recent myocardial infarction or ventricular arrhythmia and those with severe renal impairment).</p><p>BIRATO&nbsp;should&nbsp;be&nbsp;used&nbsp;with&nbsp;caution&nbsp;in&nbsp;patients&nbsp;with&nbsp;a&nbsp;history&nbsp;of&nbsp;cardiovascular&nbsp;disease. The Phase&nbsp;3&nbsp;studiesconducted&nbsp;with&nbsp;abiraterone&nbsp;excluded&nbsp;patients&nbsp;with&nbsp;uncontrolled hypertension, clinically&nbsp;significant&nbsp;heart&nbsp;disease&nbsp;asevidenced&nbsp;by&nbsp;myocardial&nbsp;infarction,&nbsp;or&nbsp;arterial&nbsp;thrombotic events in&nbsp;the past 6 months, severe or unstable angina, or New York&nbsp;Heart Association&nbsp;Class (NYHA) III or IV heart failure (study 301) or Class II to IV heart failure (studies 3011 and 302)&nbsp;or&nbsp;cardiac&nbsp;ejection&nbsp;fraction&nbsp;measurement&nbsp;of&nbsp;&lt;&nbsp;50%.&nbsp;In&nbsp;studies&nbsp;3011&nbsp;and&nbsp;302,&nbsp;patients&nbsp;with atrial&nbsp;fibrillation,&nbsp;or&nbsp;other&nbsp;cardiac&nbsp;arrhythmia&nbsp;requiring&nbsp;medical&nbsp;therapy&nbsp;were&nbsp;excluded.&nbsp;Safety in&nbsp;patients&nbsp;with&nbsp;leftventricular&nbsp;ejection&nbsp;fraction&nbsp;(LVEF)&nbsp;&lt;&nbsp;50%&nbsp;or&nbsp;NYHA&nbsp;Class&nbsp;III&nbsp;or&nbsp;IV&nbsp;heart failure (in&nbsp;study&nbsp;301) or NYHA&nbsp;Class II to IV&nbsp;heart failure (in&nbsp;studies 3011 and 302) was not established (see sections 4.8 and 5.1).</p><p>Before treating patients with a significant risk for congestive heart failure (e.g. a history of cardiac failure, uncontrolled&nbsp;hypertension, or&nbsp;cardiac&nbsp;events&nbsp;such&nbsp;as ischaemic heart disease), consider obtaining&nbsp;an assessment&nbsp;ofcardiac function&nbsp;(e.g. echocardiogram). Before&nbsp;treatment with BIRATO, cardiac failure should be treated and cardiac function optimised.</p><p>Hypertension, hypokalaemia and fluid retention should be corrected and controlled. During treatment, bloodpressure, serum&nbsp;potassium, fluid&nbsp;retention&nbsp;(weight gain, peripheral&nbsp;oedema), and other signs&nbsp;and symptoms&nbsp;ofcongestive heart failure should be monitored every&nbsp;2 weeks for 3&nbsp;months, then monthly&nbsp;thereafter and abnormalities corrected. QT&nbsp;prolongation&nbsp;has been observed in patients experiencing hypokalaemia in association with abiraterone treatment. Assess&nbsp;cardiac&nbsp;function&nbsp;as&nbsp;clinically&nbsp;indicated,&nbsp;institute&nbsp;appropriate&nbsp;management&nbsp;and&nbsp;consider discontinuation&nbsp;of&nbsp;this&nbsp;treatment if&nbsp;there is&nbsp;a&nbsp;clinically&nbsp;significant decrease in&nbsp;cardiac function (see section 4.2).</p><p><u>Hepatotoxicity&nbsp;and&nbsp;hepatic&nbsp;impairment</u></p><p>Marked increases in liver enzymes leading to treatment discontinuation or dose modification occurred in controlled clinical studies (see section 4.8). Serum&nbsp;transaminase levels should be measured prior to starting treatment, every&nbsp;two weeks for the first three months of&nbsp;treatment, and monthly thereafter. If clinical symptoms or signs suggestive of hepatotoxicity develop,&nbsp;serum transaminases should be measured immediately. If at any time the ALT or AST rises above&nbsp;5&nbsp;times&nbsp;the&nbsp;ULN,&nbsp;treatment&nbsp;should&nbsp;be&nbsp;interrupted&nbsp;immediately&nbsp;and&nbsp;liver&nbsp;function&nbsp;closely monitored. Retreatment may&nbsp;take place only&nbsp;after return&nbsp;of liver function&nbsp;tests&nbsp;to&nbsp;the patient&#39;s baseline and at a reduced dose level (see section 4.2).</p><p>If patients develop severe hepatotoxicity&nbsp;(ALT or AST 20 times the ULN) anytime while on therapy, treatment should be discontinued and patients should not be re-treated.</p><p>Patients with active or symptomatic viral hepatitis were excluded from clinical trials; thus,&nbsp;there are no data to support the use of abiraterone in this population.</p><p>There are no data on the clinical safety and efficacy of multiple doses of abiraterone acetate when administered to patients with moderate or severe hepatic impairment (Child-Pugh&nbsp;Class B or C).</p><p>The use of BIRATO should be cautiously assessed in patients with moderate hepatic impairment, in whom the benefit clearly should outweigh the possible risk (see sections 4.2 and&nbsp;5.2).&nbsp;BIRATO&nbsp;should&nbsp;not&nbsp;be&nbsp;used&nbsp;in&nbsp;patientswith&nbsp;severe&nbsp;hepatic&nbsp;impairment&nbsp;(see&nbsp;sections 4.2, 4.3 and 5.2).</p><p>There&nbsp;have&nbsp;been&nbsp;rare&nbsp;post-marketing&nbsp;reports&nbsp;of&nbsp;acute&nbsp;liver&nbsp;failure&nbsp;and&nbsp;hepatitis&nbsp;fulminant,&nbsp;some with fatal outcome (see section 4.8).</p><p><u>Corticosteroid&nbsp;withdrawal&nbsp;and&nbsp;coverage&nbsp;of&nbsp;stress&nbsp;situations</u></p><p>Caution&nbsp;is&nbsp;advised&nbsp;and&nbsp;monitoring&nbsp;for&nbsp;adrenocortical&nbsp;insufficiency&nbsp;should&nbsp;occur&nbsp;if&nbsp;patients&nbsp;are withdrawn&nbsp;fromprednisone&nbsp;or&nbsp;prednisolone.&nbsp;If&nbsp;BIRATO is&nbsp;continued&nbsp;after&nbsp;corticosteroids&nbsp;are withdrawn, patients should be monitored for symptoms of mineralocorticoid excess (see information above).</p><p>In patients on prednisone or prednisolone who are subjected to unusual stress, an increased dose of corticosteroids may be indicated before, during and after the stressful situation.</p><p><u>Bone&nbsp;density</u></p><p>Decreased bone density may&nbsp;occur in men&nbsp;with metastatic advanced prostate cancer. The use of BIRATO in combination with a glucocorticoid could increase this effect.</p><p><u>Prior&nbsp;use of&nbsp;ketoconazole</u></p><p>Lower&nbsp;rates&nbsp;of&nbsp;response&nbsp;might&nbsp;be&nbsp;expected&nbsp;in&nbsp;patients&nbsp;previously&nbsp;treated&nbsp;with&nbsp;ketoconazole&nbsp;for prostate cancer.</p><p><u>Hyperglycaemia</u></p><p>The&nbsp;use&nbsp;of&nbsp;glucocorticoids&nbsp;could increase&nbsp;hyperglycaemia,&nbsp;therefore&nbsp;blood&nbsp;sugar&nbsp;should&nbsp;be measured frequently in patients with diabetes.</p><p><u>Use&nbsp;with&nbsp;chemotherapy</u></p><p>The safety and efficacy of concomitant use of abiraterone with cytotoxic chemotherapy has not been established (see section 5.1).</p><p><u>Intolerance&nbsp;to&nbsp;excipients</u></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. This medicinal&nbsp;product also contains more&nbsp;than&nbsp;1.18 mmol&nbsp;(or 27 mg) sodium per&nbsp;dose&nbsp;of&nbsp;two&nbsp;tablets.&nbsp;To be&nbsp;taken&nbsp;into consideration&nbsp;by&nbsp;patientson&nbsp;a&nbsp;controlled&nbsp;sodium&nbsp;diet.</p><p><u>Potential&nbsp;risks</u></p><p>Anaemia and sexual&nbsp;dysfunction may&nbsp;occur in men&nbsp;with metastatic prostate cancer including those undergoing treatment with BIRATO.</p><p><u>Skeletal&nbsp;muscle&nbsp;effects</u></p><p>Cases&nbsp;of&nbsp;myopathy&nbsp;and rhabdomyolysis have been&nbsp;reported&nbsp;in&nbsp;patients&nbsp;treated with&nbsp;abiraterone.&nbsp;Most cases developed within the first 6 months of treatment and recovered after abiraterone withdrawal. Caution is recommended in patients concomitantly treated with medicinal products known to be associated with myopathy/rhabdomyolysis.</p><p><u>Interactions&nbsp;with&nbsp;other&nbsp;medicinal&nbsp;products</u></p><p>Strong inducers&nbsp;of&nbsp;CYP3A4&nbsp;during&nbsp;treatment are&nbsp;to&nbsp;be&nbsp;avoided&nbsp;unless&nbsp;there is&nbsp;no&nbsp;therapeutic alternative, due to risk of decreased exposure to abiraterone (see section 4.5).</p><p><u>Combination&nbsp;of&nbsp;abiraterone&nbsp;and prednisone/prednisolone&nbsp;with&nbsp;Ra-223</u></p><p>Treatment with abiraterone and prednisone/prednisolone in combination with Ra-223 is contraindicated&nbsp;(see&nbsp;section4.3)&nbsp;due&nbsp;to an&nbsp;increased&nbsp;risk&nbsp;of&nbsp;fractures&nbsp;and&nbsp;a&nbsp;trend for&nbsp;increased mortality&nbsp;among&nbsp;asymptomatic&nbsp;or&nbsp;mildlysymptomatic prostate&nbsp;cancer&nbsp;patients&nbsp;as&nbsp;observed in clinical trials.</p><p>It is recommended that subsequent treatment with Ra-223 is not initiated for at least 5 days after the last administration of BIRATO in combination with prednisone/prednisolone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect&nbsp;of&nbsp;food&nbsp;on&nbsp;abiraterone&nbsp;acetate</u></p><p>Administration with food significantly increases the absorption of abiraterone acetate. The efficacy and safety when given with food have not been established therefore this medicinal product must not be taken with food (see sections 4.2 and 5.2)</p><p><u>Interactions&nbsp;with&nbsp;other&nbsp;medicinal&nbsp;products</u></p><p><em>Potential&nbsp;for&nbsp;other&nbsp;medicinal&nbsp;products&nbsp;to&nbsp;affect&nbsp;abiraterone&nbsp;exposures</em></p><p>In a clinical pharmacokinetic interaction study of healthy subjects pretreated with a strong CYP3A4&nbsp;inducerrifampicin,&nbsp;600&nbsp;mg&nbsp;daily&nbsp;for&nbsp;6&nbsp;days followed&nbsp;by&nbsp;a&nbsp;single&nbsp;dose&nbsp;of&nbsp;abiraterone&nbsp;acetate 1,000 mg, the mean plasma AUC&infin;&nbsp;of abiraterone was decreased by 55%.</p><p>Strong inducers&nbsp;of&nbsp;CYP3A4 (e.g.,&nbsp;phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine,&nbsp;phenobarbital, St John&#39;s wort [<em>Hypericum perforatum</em>]) during treatment are to be avoided, unless there is no therapeutic alternative.</p><p>In&nbsp;a separate clinical&nbsp;pharmacokinetic interaction study&nbsp;of&nbsp;healthy&nbsp;subjects, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone.</p><p><em>Potential&nbsp;to&nbsp;affect&nbsp;exposures&nbsp;to&nbsp;other&nbsp;medicinal&nbsp;products</em></p><p>Abiraterone is&nbsp;an inhibitor&nbsp;of&nbsp;the hepatic drug-metabolising enzymes&nbsp;CYP2D6 and CYP2C8. In&nbsp;a&nbsp;study&nbsp;to determine&nbsp;the&nbsp;effects&nbsp;of&nbsp;abiraterone&nbsp;acetate&nbsp;(plus&nbsp;prednisone) on&nbsp;a&nbsp;single&nbsp;dose&nbsp;of the&nbsp;CYP2D6&nbsp;substratedextromethorphan,&nbsp;the&nbsp;systemic&nbsp;exposure&nbsp;(AUC)&nbsp;of&nbsp;dextromethorphan was increased approximately 2.9 fold. The AUC24 for dextrorphan, the active metabolite of dextromethorphan, increased approximately 33%.</p><p>Caution is advised when administering with medicinal products activated by or metabolised by&nbsp;CYP2D6, particularly&nbsp;with medicinal&nbsp;products&nbsp;that have a narrow&nbsp;therapeutic index. Dose reduction of medicinal products with a narrow therapeutic index that are metabolised by CYP2D6 should be considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol, propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone,&nbsp;flecainide,&nbsp;codeine,&nbsp;oxycodone&nbsp;and&nbsp;tramadol&nbsp;(the&nbsp;latter&nbsp;three&nbsp;medicinal&nbsp;products requiring CYP2D6 to form their active analgesic metabolites).</p><p>In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by 46% and the AUCs for M-III and M-IV, the active metabolites of pioglitazone, each&nbsp;decreased by&nbsp;10% when&nbsp;pioglitazone was given&nbsp;together with&nbsp;a single dose&nbsp;of&nbsp;1,000&nbsp;mg abiraterone acetate.</p><p>Although&nbsp;these&nbsp;results indicate&nbsp;that no clinically&nbsp;meaningful&nbsp;increases in&nbsp;exposure&nbsp;are&nbsp;expected&nbsp;when Abiraterone Acetate is combined with medicinal products that are predominantly eliminated&nbsp;by&nbsp;CYP2C8,&nbsp;patients&nbsp;should&nbsp;bemonitored&nbsp;for&nbsp;signs&nbsp;of&nbsp;toxicity&nbsp;related&nbsp;to&nbsp;a&nbsp;CYP2C8 substrate with a narrow therapeutic index if used concomitantly.</p><p><em>In vitro</em>, the major metabolites abiraterone sulphate and N-oxide abiraterone sulphate were shown&nbsp;to&nbsp;inhibit&nbsp;thehepatic&nbsp;uptake&nbsp;transporter&nbsp;OATP1B1&nbsp;and&nbsp;as&nbsp;a&nbsp;consequence&nbsp;it&nbsp;may&nbsp;increase the concentrations of medicinal products eliminated by OATP1B1. There are no clinical data available to confirm transporter based interaction.</p><p><u>Use&nbsp;with&nbsp;products&nbsp;known&nbsp;to prolong QT&nbsp;interval</u></p><p>Since androgen deprivation treatment may prolong the QT interval, caution is advised when administering BIRATO with medicinal products known to prolong the QT interval or medicinal products able to induce torsades de pointes such as class IA (e.g. Quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc.</p><p><u>Use&nbsp;with&nbsp;Spironolactone</u></p><p>Spironolactone binds to the androgen receptor and may increase prostate specific antigen (PSA) levels. Use with BIRATO is not recommended (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women&nbsp;of&nbsp;childbearing&nbsp;potential</u></p><p>There are no human data on the use of Abiraterone Acetate in pregnancy and this medicinal product is not for use in women of childbearing potential.</p><p><u>Contraception&nbsp;in&nbsp;males&nbsp;and&nbsp;females</u></p><p>It is not known whether abiraterone or its metabolites are present in semen. A condom is required if the patient is engaged in sexual activity with a pregnant woman. If the patient is engaged in sex with a woman of childbearing potential, a condom is required along with another effective contraceptive method. Studies in animals have shown reproductive toxicity (see section 5.3).</p><p><u>Pregnancy</u></p><p>BIRATO is&nbsp;not&nbsp;for&nbsp;use&nbsp;in&nbsp;women&nbsp;and&nbsp;is&nbsp;contraindicated&nbsp;in&nbsp;women&nbsp;who are&nbsp;or&nbsp;may&nbsp;potentially be pregnant (see section 4.3 and 5.3).</p><p><u>Breast-feeding</u></p><p>BIRATO&nbsp;is&nbsp;not&nbsp;for&nbsp;use&nbsp;in&nbsp;women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Abiraterone affected fertility in male and female rats, but these effects were fully reversible (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Abiraterone&nbsp;Acetate&nbsp;has&nbsp;no&nbsp;or&nbsp;negligible&nbsp;influence&nbsp;on&nbsp;the&nbsp;ability&nbsp;to&nbsp;drive&nbsp;and&nbsp;use&nbsp;machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Summary&nbsp;of&nbsp;the&nbsp;safety&nbsp;profile</em></p><p>In an analysis of adverse reactions of composite Phase 3 studies with Abiraterone Acetate, adverse reactions that were observed in &ge;10% of patients were peripheral oedema, hypokalaemia, hypertension urinary tract infection, and alanine aminotransferase increased and/or aspartate aminotransferase increased.</p><p>Other important adverse reactions include cardiac disorders, hepatotoxicity, fractures, and allergic alveolitis.</p><p>Abiraterone Acetate may cause hypertension, hypokalaemia and fluid retention as a pharmacodynamic consequence of its mechanism of action. In Phase 3 studies, anticipated mineralocorticoid adverse reactions were seen more commonly in patients treated with abiraterone acetate than in patients treated with placebo: hypokalaemia 18% vs.8%, hypertension&nbsp;22%&nbsp;vs.&nbsp;16%and&nbsp;fluid&nbsp;retention&nbsp;(peripheral&nbsp;oedema)&nbsp;23%&nbsp;vs.&nbsp;17%,respectively. In&nbsp;patients&nbsp;treated&nbsp;with&nbsp;abiraterone&nbsp;acetate,&nbsp;CTCAE&nbsp;(version&nbsp;4.0)&nbsp;Grades&nbsp;3&nbsp;and&nbsp;4&nbsp;hypokalaemia were observed in 6% and 2% of&nbsp;patients, CTCAE (version 4.0) Grades 3 and 4 hypertension were&nbsp;observed&nbsp;in&nbsp;8%&nbsp;and5%&nbsp;of&nbsp;patients,&nbsp;and&nbsp;fluid&nbsp;retention&nbsp;(peripheral&nbsp;oedema)&nbsp;Grades&nbsp;3&nbsp;and 4&nbsp;were&nbsp;observed&nbsp;in&nbsp;1%&nbsp;and&nbsp;1%&nbsp;of&nbsp;patients,respectively.&nbsp;Mineralocorticoid&nbsp;reactions&nbsp;generally were able to be successfully&nbsp;managed medically. Concomitant use&nbsp;of&nbsp;a corticosteroid reduces the incidence and severity of these adverse reactions (see section 4.4).</p><p><u>Tabulated&nbsp;list&nbsp;of&nbsp;adverse&nbsp;reactions</u></p><p>In studies of patients with metastatic advanced prostate cancer who were using an LHRH analogue,&nbsp;or&nbsp;werepreviously&nbsp;treated&nbsp;with&nbsp;orchiectomy,&nbsp;Abiraterone&nbsp;Acetate&nbsp;was&nbsp;administered at&nbsp;a&nbsp;dose&nbsp;of&nbsp;1,000&nbsp;mg&nbsp;daily&nbsp;incombination&nbsp;with&nbsp;low&nbsp;dose&nbsp;prednisone&nbsp;or&nbsp;prednisolone&nbsp;(either&nbsp;5 or 10 mg daily depending on the indication).</p><p>Adverse reactions observed during clinical studies and post-marketing experience are listed below by frequency category. Frequency categories are defined as follows: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare&nbsp;(&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000) and not known (frequency cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing&nbsp;seriousness.</p><p><strong>Table&nbsp;1:&nbsp;Adverse&nbsp;reactions&nbsp;identified&nbsp;in&nbsp;clinical&nbsp;studies&nbsp;and&nbsp;post-marketing</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System&nbsp;Organ&nbsp;Class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse&nbsp;reaction&nbsp;and&nbsp;frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections&nbsp;and&nbsp;infestations</p></td><td style="vertical-align:top"><p>very&nbsp;common:&nbsp;urinary&nbsp;tract&nbsp;infection common: sepsis</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine&nbsp;disorders</p></td><td style="vertical-align:top"><p>uncommon:&nbsp;adrenal&nbsp;insufficiency</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism&nbsp;and&nbsp;nutrition&nbsp;disorders</p></td><td style="vertical-align:top"><p>very common: hypokalaemia common:&nbsp;hypertriglyceridaemia</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac&nbsp;disorders</p></td><td style="vertical-align:top"><p>common:&nbsp;cardiac&nbsp;failure*,&nbsp;angina&nbsp;pectoris, atrial fibrillation, tachycardia</p><p>uncommon:&nbsp;other&nbsp;arrhythmias</p><p>not&nbsp;&nbsp;&nbsp;&nbsp;known:&nbsp;&nbsp;&nbsp;&nbsp;myocardial&nbsp;&nbsp;&nbsp;&nbsp;infarction,&nbsp;&nbsp;&nbsp;&nbsp;QT&nbsp;prolongation (see sections 4.4 and 4.5)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular&nbsp;disorders</p></td><td style="vertical-align:top"><p>very&nbsp;common:&nbsp;hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,&nbsp;thoracic&nbsp;and&nbsp;mediastinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>rare:&nbsp;allergic&nbsp;alveolitis&nbsp;<sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal&nbsp;disorders</p></td><td style="vertical-align:top"><p>very&nbsp;common:&nbsp;diarrhoea common: dyspepsia</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary&nbsp;disorders</p></td><td style="vertical-align:top"><p>very common: alanine aminotransferase increased and/or aspartate aminotransferase increased&nbsp;<sup>b</sup></p><p>rare: hepatitis fulminant, acute hepatic&nbsp;failure</p></td></tr><tr><td style="vertical-align:top"><p>Skin&nbsp;and&nbsp;subcutaneous&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>common:&nbsp;rash</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal&nbsp;and&nbsp;connective&nbsp;tissue&nbsp;disorders</p></td><td style="vertical-align:top"><p>uncommon:&nbsp;myopathy,&nbsp;rhabdomyolysis</p></td></tr><tr><td style="vertical-align:top"><p>Renal&nbsp;and&nbsp;urinary&nbsp;disorders</p></td><td style="vertical-align:top"><p>common:&nbsp;haematuria</p></td></tr><tr><td style="vertical-align:top"><p>General&nbsp;disorders&nbsp;and&nbsp;administration&nbsp;site&nbsp;conditions</p></td><td style="vertical-align:top"><p>very&nbsp;common:&nbsp;oedema&nbsp;peripheral</p></td></tr><tr><td style="vertical-align:top"><p>Injury,&nbsp;poisoning&nbsp;and&nbsp;procedural&nbsp;complications</p></td><td style="vertical-align:top"><p>common:&nbsp;fractures**</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>*&nbsp;Cardiac&nbsp;failure&nbsp;also&nbsp;includes&nbsp;congestive&nbsp;heart&nbsp;failure,&nbsp;left&nbsp;ventricular&nbsp;dysfunction&nbsp;and&nbsp;ejection&nbsp;fraction&nbsp;decreased</p><p>**&nbsp;Fractures&nbsp;includes&nbsp;osteoporosis&nbsp;and&nbsp;all&nbsp;fractures&nbsp;with&nbsp;the&nbsp;exception of&nbsp;pathological&nbsp;fractures</p><p><sup>a</sup>&nbsp;Spontaneous&nbsp;report&nbsp;from&nbsp;post-marketing&nbsp;experience</p><p><sup>b</sup>&nbsp;Alanine aminotransferase increased and/or aspartate aminotransferase increased includes ALT&nbsp;increased, AST increased, and hepatic function abnormal.</p></td></tr></tbody></table><p>The following CTCAE (version 4.0) Grade 3 adverse reactions occurred in patients treated with abiraterone acetate: hypokalaemia 5%; urinary tract infection 2%; alanine aminotransferase&nbsp;increased&nbsp;and/or&nbsp;aspartate&nbsp;aminotransferaseincreased&nbsp;4%;&nbsp;hypertension&nbsp;6%; fractures 2%; peripheral oedema, cardiac failure, and atrial fibrillation 1% each. CTCAE (version&nbsp;4.0) Grade&nbsp;3&nbsp;hypertriglyceridaemia&nbsp;and&nbsp;angina&nbsp;pectoris&nbsp;occurred&nbsp;in&nbsp;&lt;&nbsp;1%&nbsp;of&nbsp;patients. CTCAE (version 4.0) Grade 4 urinary tract infection, alanine aminotransferase increased and/or aspartate aminotransferase increased, hypokalemia, cardiac failure, atrial fibrillation, and fractures occurred in &lt; 1% of patients.</p><p>A higher incidence of hypertension and hypokalemia was observed in the hormone sensitive population (study 3011). Hypertension was reported in 36.7% of patients in the hormone sensitive population (study 3011) compared to 11.8% and 20.2% in studies 301 and 302,&nbsp;respectively.</p><p>Hypokalemia was observed in 20.4% of patients in the hormone sensitive population (study 3011) compared to 19.2% and 14.9% in 301 and 302, respectively).</p><p>The incidence and severity of adverse events was higher in the subgroup of patients with baseline ECOG2 performance status grade and also in elderly patients (&ge;75 years).</p><p><u>Description&nbsp;of&nbsp;selected&nbsp;adverse&nbsp;reactions</u></p><p><em>Cardiovascular</em><em>&nbsp;</em><em>reactions</em></p><p>The three Phase 3 studies excluded patients with uncontrolled hypertension, clinically significant heart disease as evidenced by myocardial infarction, or arterial thrombotic events in the past 6 months, severe or unstable angina, or NYHA&nbsp;Class III or IV heart failure (study 301) or Class II to IV heart failure (studies 3011 and 302) or cardiac ejection fraction measurement of &lt; 50%. All patients enrolled (both active and placebo-treated patients) were concomitantly treated with androgen deprivation therapy, predominantly with the use of LHRH analogues, which has been associated with diabetes, myocardial infarction, cerebrovascular accident and sudden cardiac death.</p><p>The incidence of cardiovascular adverse reactions in the Phase 3 studies in patients taking abiraterone acetate versus patients taking placebo were as follows: atrial fibrillation&nbsp;2.6% vs. 2.0%,&nbsp;tachycardia&nbsp;1.9%&nbsp;vs.&nbsp;1.0%,angina&nbsp;pectoris&nbsp;1.7%&nbsp;vs.&nbsp;0.8%,&nbsp;cardiac&nbsp;failure&nbsp;0.7%&nbsp;vs.&nbsp;0.2%,&nbsp;and&nbsp;arrhythmia&nbsp;0.7%&nbsp;vs.&nbsp;0.5%.</p><p><em>Hepatotoxicity</em></p><p>Hepatotoxicity&nbsp;with&nbsp;elevated&nbsp;ALT,&nbsp;AST&nbsp;and&nbsp;total&nbsp;bilirubin&nbsp;has&nbsp;been&nbsp;reported&nbsp;in&nbsp;patients&nbsp;treated with abiraterone acetate. Across Phase 3 clinical studies, hepatotoxicity grades 3 and 4 (e.g., ALT or AST increases of &gt; 5 x ULN or bilirubin increases &gt; 1.5 x ULN) were reported in approximately 6% of patients who received abiraterone acetate, typically during the first 3 months after starting treatment. In Study 3011, grade 3 or 4 hepatotoxicity was observed in 8.4% of patients treated with Abiraterone Acetate. Ten patients who received Abiraterone Acetate&nbsp;werediscontinued&nbsp;because&nbsp;of&nbsp;hepatotoxicity;&nbsp;two&nbsp;had&nbsp;Grade&nbsp;2&nbsp;hepatotoxicity,&nbsp;six&nbsp;had Grade&nbsp;3&nbsp;hepatotoxicity,&nbsp;and&nbsp;two&nbsp;hadGrade&nbsp;4&nbsp;hepatotoxicity.&nbsp;No&nbsp;patient&nbsp;died&nbsp;of&nbsp;hepatotoxicity in Study 3011. In the Phase 3 clinical studies, patients whose baseline ALT or AST were elevated&nbsp;were&nbsp;more&nbsp;likely&nbsp;to&nbsp;experience&nbsp;liver&nbsp;function&nbsp;test&nbsp;elevations&nbsp;than&nbsp;thosebeginning&nbsp;with normal&nbsp;values. When&nbsp;elevations&nbsp;of&nbsp;either&nbsp;ALT or&nbsp;AST &gt;&nbsp;5 x&nbsp;ULN,&nbsp;or&nbsp;elevations in&nbsp;bilirubin&nbsp;&gt; 3 x ULN were observed, abiraterone acetate was withheld or discontinued. In two instances marked increases in liver function tests occurred (see section 4.4).</p><p>These&nbsp;two&nbsp;patients&nbsp;with&nbsp;normal&nbsp;baseline&nbsp;hepatic&nbsp;function,&nbsp;experienced&nbsp;ALT&nbsp;or&nbsp;AST&nbsp;elevations 15&nbsp;to&nbsp;40&nbsp;x&nbsp;ULN&nbsp;andbilirubin&nbsp;elevations&nbsp;2&nbsp;to&nbsp;6&nbsp;x&nbsp;ULN.&nbsp;Upon&nbsp;discontinuation&nbsp;of&nbsp;treatment,&nbsp;both patients had normalisation of&nbsp;their liver function tests and one patient was re-treated without recurrence&nbsp;of&nbsp;the&nbsp;elevations.&nbsp;In&nbsp;study&nbsp;302,&nbsp;Grade&nbsp;3&nbsp;or&nbsp;4&nbsp;ALT&nbsp;orAST&nbsp;elevations&nbsp;were&nbsp;observed in&nbsp;35&nbsp;(6.5%)&nbsp;patients&nbsp;treated&nbsp;with&nbsp;abiraterone&nbsp;acetate.&nbsp;Aminotransferase&nbsp;elevationsresolved&nbsp;in all&nbsp;but&nbsp;3&nbsp;patients&nbsp;(2&nbsp;with&nbsp;new&nbsp;multiple&nbsp;liver&nbsp;metastases&nbsp;and&nbsp;1&nbsp;with&nbsp;AST&nbsp;elevation&nbsp;approximately 3 weeks after the last dose of abiraterone acetate). In Phase 3 clinical studies, treatment discontinuations&nbsp;due&nbsp;to&nbsp;ALT&nbsp;andAST&nbsp;increases&nbsp;or&nbsp;abnormal&nbsp;hepatic&nbsp;function&nbsp;were&nbsp;reported&nbsp;in 1.1%&nbsp;of&nbsp;patients&nbsp;treated&nbsp;with&nbsp;abiraterone&nbsp;acetate&nbsp;and0.6%&nbsp;of&nbsp;patients&nbsp;treated&nbsp;with&nbsp;placebo;&nbsp;no deaths were reported due to hepatotoxicity events.</p><p>In&nbsp;clinical&nbsp;trials,&nbsp;the&nbsp;risk&nbsp;for&nbsp;hepatotoxicity&nbsp;was&nbsp;mitigated&nbsp;by&nbsp;exclusion&nbsp;of&nbsp;patients&nbsp;with&nbsp;baseline hepatitis or significant abnormalities of liver function tests. In the 3011 trial, patients with baseline ALT and AST &gt; 2.5 X ULN, bilirubin &gt; 1.5 X ULN or those with active or symptomatic&nbsp;viral&nbsp;hepatitis&nbsp;or&nbsp;chronic&nbsp;liver&nbsp;disease;&nbsp;ascites&nbsp;orbleeding&nbsp;disorders&nbsp;secondary&nbsp;to hepatic&nbsp;dysfunction&nbsp;were&nbsp;excluded.&nbsp;In&nbsp;the&nbsp;301&nbsp;trial,&nbsp;patients&nbsp;with&nbsp;baseline&nbsp;ALT andAST&nbsp;&ge;&nbsp;2.5 x ULN in the absence of liver metastases and &gt; 5 x ULN in the presence of liver metastases wereexcluded.&nbsp;In the&nbsp;302 trial,&nbsp;patients with&nbsp;liver&nbsp;metastases were&nbsp;not&nbsp;eligible&nbsp;and&nbsp;patients&nbsp;with baseline ALT and AST &ge; 2.5 x ULN were excluded. Abnormal liver function tests developing in patients participating in clinical trials were vigorously managed by requiring treatment&nbsp;interruption&nbsp;and&nbsp;permitting&nbsp;re-treatment&nbsp;only&nbsp;after&nbsp;return&nbsp;of&nbsp;liver&nbsp;function&nbsp;tests&nbsp;to&nbsp;the patient&#39;s baseline (see section 4.2).</p><p>Patients with elevations of ALT or AST &gt; 20 x ULN were not re-treated. The safety of re- treatment in such patients is unknown. The mechanism for hepatotoxicity is not understood.</p><p><em>Pediatric&nbsp;Use</em></p><p>Safety&nbsp;and&nbsp;effectiveness&nbsp;of&nbsp;Abiraterone&nbsp;in&nbsp;pediatric&nbsp;patients&nbsp;have&nbsp;not&nbsp;been&nbsp;established.</p><p>&nbsp;</p><p><em>Geriatric&nbsp;Use</em></p><p>Of the total number of patients receiving Abiraterone in randomized clinical trials, 70% of patients were 65 years and over and 27% were 75 years and over. No overall differences in safety or effectiveness were observed between these elderly patients and younger patients. Other reported clinical experience has not identified differences in responses between the elderly&nbsp;and younger patients, but greater sensitivity&nbsp;of&nbsp;some&nbsp;older individuals&nbsp;cannot beruled&nbsp;out.</p><p>Reporting&nbsp;of&nbsp;suspected&nbsp;adverse&nbsp;reactions</p><p><u>To&nbsp;reports&nbsp;any&nbsp;side&nbsp;effect(s):</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important.&nbsp;It&nbsp;allows&nbsp;continuedmonitoring&nbsp;of&nbsp;the&nbsp;benefit/risk&nbsp;balance&nbsp;of&nbsp;the medicinal&nbsp;product. Healthcare&nbsp;professionals&nbsp;are&nbsp;asked&nbsp;to report anysuspected&nbsp;adverse&nbsp;reactions&nbsp;to&nbsp;the&nbsp;competent authority in Saudi Arabia as per details below:</p><p><!--[if !supportLists]--><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<!--[endif]-->The&nbsp;National&nbsp;Pharmacovigilance&nbsp;and Drug&nbsp;Safety&nbsp;Centre&nbsp;(NPC)</strong></p><p><strong>o&nbsp;Fax: +966-11-205-7662</strong></p><p><strong>o&nbsp;Call&nbsp;NPC&nbsp;at&nbsp;+966-11-2038222,&nbsp;Exts:&nbsp;2317-2356-2353-2354-2334-2340.</strong></p><p><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;<!--[endif]-->Toll&nbsp;free&nbsp;phone:&nbsp;8002490000</strong></p><p><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;<!--[endif]-->E-mail:&nbsp;npc.drug@sfda.gov.sa</strong></p><p><!--[if !supportLists]--><strong>o&nbsp;&nbsp;&nbsp;<!--[endif]-->Website:&nbsp;www.sfda.gov.sa/npc</strong></p><p>&nbsp;</p><p>To&nbsp;report&nbsp;the&nbsp;Adverse&nbsp;event&nbsp;in&nbsp;other&nbsp;GCC&nbsp;States&nbsp;-&nbsp;Please&nbsp;contact&nbsp;the&nbsp;relevant&nbsp;competent&nbsp;authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human&nbsp;experience&nbsp;of&nbsp;overdose&nbsp;with&nbsp;Abiraterone&nbsp;Acetate&nbsp;is&nbsp;limited.</p><p>There is no specific antidote. In the event of&nbsp;an overdose, administration should be withheld and general supportive measures undertaken, including monitoring for arrhythmias, hypokalaemia and for signs and symptoms of fluid retention. Liver function also should be&nbsp;assessed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic&nbsp;group:&nbsp;endocrine&nbsp;therapy,&nbsp;other&nbsp;hormone&nbsp;antagonists&nbsp;and&nbsp;related&nbsp;agents, ATC code: L02BX03</p><p>Mechanism&nbsp;of&nbsp;action</p><p>Abiraterone acetate (BIRATO) is converted&nbsp;<em>in vivo&nbsp;</em>to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17&alpha; hydroxylase/C17,20- lyase (CYP17). This enzyme is expressed in and is required for androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 catalyses the conversion of pregnenolone and progesterone into testosterone precursors, DHEA and androstenedione, respectively, by 17&alpha;-hydroxylation and cleavage of the C17,20 bond. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals (see section 4.4).</p><p>Androgen-sensitive&nbsp;prostatic&nbsp;carcinoma&nbsp;responds&nbsp;to&nbsp;treatment that&nbsp;decreases&nbsp;androgen&nbsp;levels. Androgen deprivation therapies, such as treatment with LHRH analogues or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals&nbsp;or&nbsp;in&nbsp;the&nbsp;tumour.&nbsp;Treatment&nbsp;with&nbsp;Abiraterone&nbsp;Acetate&nbsp;decreasesserum&nbsp;testosterone&nbsp;to undetectable levels (using commercial assays) when given with LHRH analogues (or&nbsp;orchiectomy).</p><p><strong><u>Pharmacodynamic</u></strong><strong><u>&nbsp;</u></strong><strong><u>effects</u></strong></p><p>Abiraterone Acetate decreases serum testosterone and other androgens to levels lower than those achieved by&nbsp;the use of&nbsp;LHRH analogues alone or&nbsp;by&nbsp;orchiectomy. This results from&nbsp;the selective inhibition of&nbsp;the CYP17 enzyme required for androgen biosynthesis. PSA serves as a&nbsp;biomarker in&nbsp;patients&nbsp;with&nbsp;prostate&nbsp;cancer. In&nbsp;a&nbsp;Phase&nbsp;3 clinicalstudy&nbsp;of&nbsp;patients&nbsp;who failed prior&nbsp;chemotherapy&nbsp;with&nbsp;taxanes,&nbsp;38%&nbsp;of&nbsp;patients&nbsp;treated&nbsp;with&nbsp;abiraterone&nbsp;acetate,versus&nbsp;10% of&nbsp;patients treated with placebo, had at least a 50% decline from&nbsp;baseline in PSA levels.</p><p><strong><u>Clinical&nbsp;efficacy&nbsp;and&nbsp;safety</u></strong></p><p>Efficacy was established in three randomised placebo-controlled multicentre Phase 3 clinical studies&nbsp;(studies&nbsp;3011,302&nbsp;and&nbsp;301)&nbsp;of&nbsp;patients&nbsp;with&nbsp;mHSPC&nbsp;and&nbsp;mCRPC.&nbsp;Study&nbsp;3011&nbsp;enrolled patients who were newly diagnosed (within 3 months of randomization) mHSPC who had high-risk prognostic factors. High-risk prognosis was defined as having at least 2 of the following 3 risk factors: (1) Gleason score of &ge;8; (2) presence of 3 or more lesions on bone scan; (3) presence of measurable visceral (excluding lymph node disease) metastasis. In the active arm, Abiraterone Acetate was administered at a dose&nbsp;of&nbsp;1000 mg daily in combination with&nbsp;low&nbsp;dose&nbsp;prednisone&nbsp;5&nbsp;mg&nbsp;once&nbsp;daily&nbsp;inaddition&nbsp;to&nbsp;ADT&nbsp;(LHRH&nbsp;agonist&nbsp;or&nbsp;orchiectomy), which was the standard of care treatment.</p><p>Patients in the control arm received ADT and placebos for both Abiraterone Acetate and prednisone. Study 302 enrolled docetaxel na&iuml;ve patients;&nbsp;whereas,&nbsp;study&nbsp;301&nbsp;enrolled&nbsp;patients&nbsp;who&nbsp;had&nbsp;received&nbsp;prior&nbsp;docetaxel.&nbsp;Patients&nbsp;were using&nbsp;an&nbsp;LHRHanalogue&nbsp;or&nbsp;were&nbsp;previously&nbsp;treated&nbsp;with&nbsp;orchiectomy.&nbsp;In&nbsp;the&nbsp;active&nbsp;treatment arm, Abiraterone Acetate was administered at a dose of 1,000 mg daily in combination with low dose prednisone or&nbsp;prednisolone 5 mg twice daily. Control&nbsp;patients&nbsp;received placebo and low dose prednisone or prednisolone 5 mg twice daily.</p><p>Changes in PSA serum concentration independently do not always predict clinical benefit. Therefore, in all studies it was recommended that patients be maintained on their study treatments until discontinuation criteria were met as specified below for each study. In all studies spironolactone use was not allowed as spironolactone binds to the androgen receptor and may increase PSA levels.</p><p>Study&nbsp;3011&nbsp;(patients&nbsp;with&nbsp;newly&nbsp;diagnosed&nbsp;high&nbsp;risk&nbsp;mHSPC)</p><p>In Study 3011, (n=1199) the median age of enrolled patients was 67 years. The number of patients treated with Abiraterone Acetate by racial group was Caucasian 832 (69.4%), Asian 246 (20.5%), Black or African American 25 (2.1%), other 80 (6.7%), unknown/not reported 13 (1.1%), and American Indian or Alaska Native 3 (0.3%). The ECOG performance status was 0 or 1 for 97% of patients. Patients with known brain metastasis, uncontrolled hypertension, significant heart disease, or NYHA Class II-IV heart failure were excluded. Patients that were treated with prior pharmacotherapy, radiation therapy, or surgery for metastatic prostate cancer were excluded with the exception of up to 3 months of ADT or 1 course of palliative radiation or surgical therapy to treat symptoms resulting from metastatic&nbsp;disease.</p><p>Co-primary efficacy endpoints were overall survival (OS) and radiographic progression-free survival (rPFS). The median baseline pain score, as measured by the Brief Pain Inventory Short Form (BPI-SF) was 2.0 in both the treatment and Placebo groups. In addition&nbsp;to&nbsp;the&nbsp;co-primary&nbsp;endpoint&nbsp;measures,&nbsp;benefit&nbsp;was&nbsp;also&nbsp;assessedusing&nbsp;time&nbsp;to&nbsp;skeletal- related event (SRE), time to subsequent therapy for prostate cancer, time to initiation of chemotherapy, time to pain progression, and time to PSA progression.</p><p>Treatment continued until disease progression, withdrawal of consent, the occurrence of unacceptable toxicity, or death. Radiographic progression-free survival&nbsp;was defined as the time from&nbsp;randomization&nbsp;to the&nbsp;occurrence&nbsp;of&nbsp;radiographic&nbsp;progression&nbsp;or&nbsp;deathfrom&nbsp;any&nbsp;cause.&nbsp;Radiographic&nbsp;progression included progression by bone scan (according to modified PCWG2) or progression of soft tissue lesions by CT or MRI (according to RECIST 1.1). A significant difference in rPFS between treatment groups was observed (see Table 2 and Figure 1).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;2:&nbsp;Radiographic&nbsp;Progression-Free&nbsp;Survival&nbsp;-&nbsp;Stratified&nbsp;Analysis;&nbsp;Intent-to-treat Population (Study PCR3011)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AA-P</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>Subjects&nbsp;randomised</p></td><td style="vertical-align:top"><p>597</p></td><td style="vertical-align:top"><p>602</p></td></tr><tr><td style="vertical-align:top"><p>Event</p></td><td style="vertical-align:top"><p>239&nbsp;(40.0%)</p></td><td style="vertical-align:top"><p>354&nbsp;(58.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Censored</p></td><td style="vertical-align:top"><p>358&nbsp;(60.0%)</p></td><td style="vertical-align:top"><p>248&nbsp;(41.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Time&nbsp;to&nbsp;Event&nbsp;(months)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>33.02&nbsp;(29.57,&nbsp;NE)</p></td><td style="vertical-align:top"><p>14.78&nbsp;(14.69,&nbsp;18.27)</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>(0.0+,&nbsp;41.0+)</p></td><td style="vertical-align:top"><p>(0.0+,&nbsp;40.6+)</p></td></tr><tr><td style="vertical-align:top"><p>p&nbsp;value<sup>a</sup></p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio&nbsp;(95%&nbsp;CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>0.466&nbsp;(0.394,&nbsp;0.550)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Note:&nbsp;+=&nbsp;censored&nbsp;observation,&nbsp;NE=not estimable. The&nbsp;radiographic&nbsp;progression&nbsp;and&nbsp;death are&nbsp;considered&nbsp;in&nbsp;defining&nbsp;the&nbsp;rPFS&nbsp;event.&nbsp;AA-P=&nbsp;subjects&nbsp;who&nbsp;received&nbsp;abiraterone&nbsp;acetate and prednisone.</p><p><sup>a</sup>p value is from a log-rank test stratified by ECOG PS score (0/1 or 2) and visceral lesion (absent or present).</p><p><sup>b</sup>&nbsp;Hazard&nbsp;ratio&nbsp;is&nbsp;from&nbsp;stratified&nbsp;proportional&nbsp;hazards&nbsp;model. Hazard&nbsp;ratio&nbsp;&lt;1&nbsp;favors&nbsp;AA-P.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;1:&nbsp;Kaplan-Meier&nbsp;Plot&nbsp;of&nbsp;Radiographic&nbsp;Progression-free&nbsp;Survival;&nbsp;Intent-to-treat Population (StudyPCR3011)</strong></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="342" height="200" src="blob:https://sdi.sfda.gov.sa/c77fed36-ab42-468f-8a15-2ed181958e00" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>A&nbsp;statistically&nbsp;significant improvement in&nbsp;OS in favor of&nbsp;AA-P plus ADT was observed with a 38% reduction in the risk of death compared to Placebo plus ADT (HR=0.621; 95% CI: 0.509,&nbsp;0.756;&nbsp;p&lt;0.0001,&nbsp;crossing&nbsp;the&nbsp;pre-specified&nbsp;boundary&nbsp;for&nbsp;OS&nbsp;at&nbsp;Interim&nbsp;Analysis&nbsp;1&nbsp;of&nbsp;0.010&nbsp;(see&nbsp;Table&nbsp;3&nbsp;and&nbsp;Figure&nbsp;2).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;3:&nbsp;Overall&nbsp;Survival,&nbsp;Stratified&nbsp;Analysis;&nbsp;Intent-to-treat&nbsp;Population&nbsp;(StudyPCR3011)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>AA-P</p></td><td style="vertical-align:top"><p>Placebo</p></td></tr><tr><td style="vertical-align:top"><p>Subjects&nbsp;randomised</p></td><td style="vertical-align:top"><p>597</p></td><td style="vertical-align:top"><p>602</p></td></tr><tr><td style="vertical-align:top"><p>Event</p></td><td style="vertical-align:top"><p>169&nbsp;(28.3&nbsp;%)</p></td><td style="vertical-align:top"><p>237&nbsp;(58.8%)</p></td></tr><tr><td style="vertical-align:top"><p>Censored</p></td><td style="vertical-align:top"><p>428&nbsp;(71.7%)</p></td><td style="vertical-align:top"><p>365&nbsp;(41.2%)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Time&nbsp;to&nbsp;Event&nbsp;(months)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>NE( NE,&nbsp;NE)</p></td><td style="vertical-align:top"><p>34.73&nbsp;(33.05&nbsp;,&nbsp;NE)</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>(0.1,&nbsp;43.5+)</p></td><td style="vertical-align:top"><p>(1.4+,&nbsp;43.5+)</p></td></tr><tr><td style="vertical-align:top"><p>p&nbsp;value<sup>a</sup></p></td><td style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio&nbsp;(95%&nbsp;CI)<sup>b</sup></p></td><td style="vertical-align:top"><p>0.&nbsp;621&nbsp;(0.509,&nbsp;0.756)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>Note:+=&nbsp;censored&nbsp;observation,&nbsp;NE&nbsp;=&nbsp;not&nbsp;estimable.&nbsp;AA-P=&nbsp;subjects&nbsp;who&nbsp;received abiraterone acetate and prednisone</p><p><sup>a</sup>&nbsp;p value&nbsp;is from log-rank test stratified by ECOG PS score (0/1 or 2) and visceral lesion(absent or present).</p><p><sup>b</sup>&nbsp;Hazard&nbsp;ratio&nbsp;is from&nbsp;stratified&nbsp;proportional&nbsp;hazards model. Hazard&nbsp;ratio&nbsp;&lt;1&nbsp;favors&nbsp;AA-P.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Figure&nbsp;2:&nbsp;Kaplan-Meier&nbsp;Plot&nbsp;of&nbsp;Overall&nbsp;Survival; Intent-to-treat&nbsp;Population&nbsp;(Study&nbsp;PCR3011)</strong></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="386" height="199" src="blob:https://sdi.sfda.gov.sa/f451352b-1a5f-4acd-9f3d-a2dc526cc1a2" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Subgroup&nbsp;analyses&nbsp;consistently&nbsp;favor&nbsp;treatment&nbsp;with&nbsp;Abiraterone&nbsp;Acetate.&nbsp;The&nbsp;treatment&nbsp;effect of&nbsp;AA-P&nbsp;on&nbsp;rPFS&nbsp;andOS&nbsp;across&nbsp;the&nbsp;pre-specified&nbsp;subgroups&nbsp;was&nbsp;favorable&nbsp;and&nbsp;consistent&nbsp;with the overall study population, except for the subgroup of ECOG score of 2 where no trend towards benefit was observed, however the small sample size (n=40) limits drawing any meaningful conclusion.</p><p>In addition to the observed improvements in overall survival and rPFS, benefit was demonstrated for Abiraterone Acetate vs. Placebo treatment in all prospectively-defined secondary endpoint measures as follows:</p><p>Time&nbsp;to&nbsp;skeletal-related&nbsp;event&nbsp;(SRE):&nbsp;There&nbsp;was&nbsp;a&nbsp;30%&nbsp;reduction&nbsp;in&nbsp;the&nbsp;risk&nbsp;of&nbsp;skeletal-related events (HR = 0.703; 95% CI: [0.539, 0.916], p = 0.0086). The median time to SRE has not been reached for the Abiraterone Acetate or placebo study arm.</p><p>Time&nbsp;to&nbsp;PSA&nbsp;progression&nbsp;based&nbsp;on&nbsp;PCWG2&nbsp;criteria:&nbsp;The&nbsp;median&nbsp;time&nbsp;to&nbsp;PSA&nbsp;progression&nbsp;was&nbsp;33.2 months for patients&nbsp;receiving Abiraterone Acetate and 7.4 months for patients&nbsp;receiving placebo (HR = 0.299; 95% CI: [0.255, 0.352], p &lt;0.0001).</p><p>Time to subsequent therapy: The median time to subsequent therapy at the time of interim analysis was not reached for patients receiving Abiraterone Acetate and was 21.6 months for patients receiving placebo (HR = 0.415; 95% CI: [0.346, 0.497], p &lt;0.0001).</p><p>Time to initiation of chemotherapy: The median time to initiation of chemotherapy was not reached&nbsp;for&nbsp;patientsreceiving&nbsp;Abiraterone&nbsp;Acetate&nbsp;and&nbsp;was&nbsp;38.9&nbsp;months&nbsp;for&nbsp;patients&nbsp;receiving placebo (HR = 0.443; 95% CI: [0.349, 0.561], p &lt; 0.0001).</p><p>Time to pain progression: The median time to pain progression was not reached for patients receiving&nbsp;AbirateroneAcetate&nbsp;and&nbsp;was&nbsp;16.6&nbsp;months&nbsp;for&nbsp;patients&nbsp;receiving&nbsp;placebo&nbsp;(HR&nbsp;= 0.695; 95% CI: [0.583, 0.829], p &lt;0.0001).</p><p>The&nbsp;majority&nbsp;of&nbsp;exploratory&nbsp;endpoints&nbsp;favored&nbsp;treatment&nbsp;with&nbsp;abiraterone&nbsp;acetate&nbsp;and prednisone (AA-P) over Placebo.</p><p>&nbsp;</p><p><u>Study&nbsp;302 (chemotherapy&nbsp;na&iuml;ve&nbsp;patients)</u></p><p>This study enrolled chemotherapy na&iuml;ve patients who were asymptomatic or mildly symptomatic and for whomchemotherapy was not yet clinically indicated. A&nbsp;score&nbsp;of&nbsp;0-1 on Brief Pain Inventory-Short Form (BPI-SF) worst pain in last 24 hours was considered asymptomatic, and a score of 2-3 was considered mildly symptomatic.</p><p>In&nbsp;study&nbsp;302, (n&nbsp;= 1,088)&nbsp;the median&nbsp;age of&nbsp;enrolled patients&nbsp;was&nbsp;71 years for patients&nbsp;treated with Abiraterone Acetate plus prednisone or prednisolone and 70 years for patients treated with&nbsp;placebo&nbsp;plus&nbsp;prednisone&nbsp;orprednisolone.&nbsp;The&nbsp;number&nbsp;of&nbsp;patients&nbsp;treated&nbsp;with&nbsp;Abiraterone Acetate by racial group was Caucasian 520 (95.4%), Black 15 (2.8%), Asian 4 (0.7%) and other 6&nbsp;(1.1%). The Eastern&nbsp;Cooperative Oncology&nbsp;Group&nbsp;(ECOG) performance status was 0 for 76% of&nbsp;patients, and 1 for 24%&nbsp;of&nbsp;patients in both&nbsp;arms. Fifty&nbsp;percent of&nbsp;patients&nbsp;had only bone metastases, an additional 31% of patients had bone and soft tissue or lymph node metastases and 19% of patients had only soft tissue or lymph node metastases. Patients with visceral metastases were excluded. Co-primary efficacy endpoints were overall survival and radiographic progression-free survival (rPFS). In addition to the co-primary endpoint measures,&nbsp;benefit was&nbsp;also assessed&nbsp;using time&nbsp;to&nbsp;opiate&nbsp;use for&nbsp;cancer&nbsp;pain,&nbsp;time&nbsp;toinitiation of&nbsp;cytotoxic&nbsp;chemotherapy,&nbsp;time&nbsp;to&nbsp;deterioration&nbsp;in&nbsp;ECOG&nbsp;performance&nbsp;score&nbsp;by&nbsp;&ge;&nbsp;1&nbsp;point&nbsp;and time&nbsp;to&nbsp;PSAprogression&nbsp;based&nbsp;on&nbsp;Prostate&nbsp;Cancer&nbsp;Working&nbsp;Group-2&nbsp;(PCWG2)&nbsp;criteria.&nbsp;Study treatments&nbsp;were&nbsp;discontinued&nbsp;at&nbsp;thetime&nbsp;of&nbsp;unequivocal&nbsp;clinical&nbsp;progression.&nbsp;Treatments&nbsp;could also be&nbsp;discontinued&nbsp;at&nbsp;the&nbsp;time&nbsp;of&nbsp;confirmedradiographic&nbsp;progression&nbsp;at&nbsp;the&nbsp;discretion&nbsp;of&nbsp;the&nbsp;investigator.</p><p>Radiographic&nbsp;progression&nbsp;free&nbsp;survival&nbsp;(rPFS)&nbsp;was&nbsp;assessed&nbsp;with&nbsp;the&nbsp;use&nbsp;of&nbsp;sequential&nbsp;imaging&nbsp;studies as defined by PCWG2 criteria (for bone lesions) and modified Response Evaluation Criteria In&nbsp;Solid Tumors&nbsp;(RECIST) criteria (for soft tissue lesions). Analysis&nbsp;of&nbsp;rPFS utilised centrally reviewed radiographic assessment of progression.</p><p>At the planned rPFS analysis there were 401 events, 150 (28%) of patients treated with Abiraterone&nbsp;Acetate&nbsp;and&nbsp;251(46%)&nbsp;of&nbsp;patients&nbsp;treated&nbsp;with&nbsp;placebo&nbsp;had&nbsp;radiographic&nbsp;evidence of progression or had died. A significant difference in rPFS between treatment groups was observed (see Table 4 and Figure 3).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;4:&nbsp;Study&nbsp;302:&nbsp;Radiographic&nbsp;progression-free&nbsp;survival&nbsp;of&nbsp;patients&nbsp;treated&nbsp;with</strong></p><p><strong>either&nbsp;Abiraterone&nbsp;Acetate&nbsp;or&nbsp;placebo&nbsp;in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone plus LHRH analogues or prior orchiectomy</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abiraterone&nbsp;Acetate</p><p>(N&nbsp;=&nbsp;546)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N&nbsp;=&nbsp;542)</p></td></tr><tr><td style="vertical-align:top"><p>Radiographic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progression-</p><p>free&nbsp;Survival&nbsp;(rPFS)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Progression&nbsp;or&nbsp;death</p></td><td style="vertical-align:top"><p>150(28%)</p></td><td style="vertical-align:top"><p>251(46%)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;rPFS&nbsp;in&nbsp;months</p></td><td style="vertical-align:top"><p>Not&nbsp;reached</p></td><td style="vertical-align:top"><p>8.3</p></td></tr><tr><td style="vertical-align:top"><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>(11.66;&nbsp;NE)</p></td><td style="vertical-align:top"><p>(8.12;&nbsp;8.54)</p></td></tr><tr><td style="vertical-align:top"><p>p-value*</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio**&nbsp;(95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.425&nbsp;(0.347;&nbsp;0.522)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>NE =&nbsp;Not&nbsp;estimated</p><p>*&nbsp;p-value&nbsp;is&nbsp;derived&nbsp;from&nbsp;a&nbsp;log-rank&nbsp;test stratified&nbsp;by&nbsp;baseline&nbsp;ECOG&nbsp;score&nbsp;(0&nbsp;or&nbsp;1)</p><p>**&nbsp;Hazard&nbsp;ratio&nbsp;&lt;&nbsp;1&nbsp;favours&nbsp;Abiraterone&nbsp;Acetate</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Figure 3: Kaplan&nbsp;Meier curves of radiographic progression-free survival&nbsp;in&nbsp;patients&nbsp;treated with&nbsp;eitherAbiraterone&nbsp;Acetate&nbsp;or&nbsp;placebo in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone plus LHRH analogues or prior orchiectomy</p><p><img width="366" height="215" src="blob:https://sdi.sfda.gov.sa/4971fdb8-85bf-4400-bf87-a78d5bde91b6" /></p><p>AA-Abiretarone</p><p>However,&nbsp;subject&nbsp;data&nbsp;continued&nbsp;to&nbsp;be&nbsp;collected&nbsp;through&nbsp;the&nbsp;date&nbsp;of&nbsp;the&nbsp;second&nbsp;interim&nbsp;analysis of&nbsp;Overall&nbsp;survival(OS). The investigator&nbsp;radiographic&nbsp;review&nbsp;of&nbsp;rPFS&nbsp;performed&nbsp;as&nbsp;a follow up sensitivity analysis is presented in Table 5 and Figure 4.</p><p>Six&nbsp;hundred and seven&nbsp;(607) subjects&nbsp;had radiographic progression&nbsp;or&nbsp;died: 271 (50%) in&nbsp;the abiraterone acetate group and 336 (62%) in the placebo group. Treatment with abiraterone acetate&nbsp;decreased&nbsp;the&nbsp;risk&nbsp;of&nbsp;radiographicprogression&nbsp;or&nbsp;death&nbsp;by&nbsp;47%&nbsp;compared&nbsp;with&nbsp;placebo (HR = 0.530;&nbsp;95% CI: [0.451;&nbsp;0.623], p &lt; 0.0001). The medianrPFS was 16.5 months in the abiraterone acetate group and 8.3 months in the placebo group.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 5: Study 302: Radiographic progression-free survival of patients treated with either&nbsp;Abiraterone&nbsp;Acetate&nbsp;or&nbsp;placebo&nbsp;in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone plus&nbsp;LHRH&nbsp;analogues&nbsp;or&nbsp;prior&nbsp;orchiectomy&nbsp;(At&nbsp;second&nbsp;interim&nbsp;analysis&nbsp;of&nbsp;OS-</strong></p><p><strong>Investigator</strong><strong>&nbsp;</strong><strong>Review)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abiraterone&nbsp;Acetate</p><p>(N&nbsp;=&nbsp;546)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N&nbsp;=&nbsp;542)</p></td></tr><tr><td style="vertical-align:top"><p>Radiographic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Progression-</p><p>free&nbsp;Survival&nbsp;(rPFS)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Progression&nbsp;or&nbsp;death</p></td><td style="vertical-align:top"><p>271(50&nbsp;%)</p></td><td style="vertical-align:top"><p>336&nbsp;(62&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;rPFS&nbsp;in&nbsp;months</p><p>(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>16.5</p><p>(13.80;&nbsp;16.79)</p></td><td style="vertical-align:top"><p>8.3</p><p>(8.05;&nbsp;9.43)</p></td></tr><tr><td style="vertical-align:top"><p>p-value*</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio**&nbsp;(95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.530&nbsp;(0.451;&nbsp;0.623)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>*&nbsp;p-value&nbsp;is&nbsp;derived&nbsp;from&nbsp;a&nbsp;log-rank test&nbsp;stratified&nbsp;by&nbsp;baseline&nbsp;ECOG&nbsp;score&nbsp;(0&nbsp;or&nbsp;1)</p><p>**&nbsp;Hazard&nbsp;ratio&nbsp;&lt;&nbsp;1&nbsp;favours&nbsp;Abiraterone&nbsp;Acetate</p></td></tr></tbody></table><p>&nbsp;</p><p>Figure 4: Kaplan&nbsp;Meier curves of&nbsp;radiographic progression-free survival&nbsp;in&nbsp;patients&nbsp;treated with&nbsp;eitherAbiraterone&nbsp;Acetate&nbsp;or&nbsp;placebo in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or prednisolone plus LHRH analogues&nbsp;or priororchiectomy&nbsp;(At second interim&nbsp;analysis&nbsp;of&nbsp;OS-Investigator&nbsp;Review)</p><table cellpadding="0" cellspacing="0" align="left" style="background-color:#ffffff; width:388.25px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:387.75px"><img width="388" height="215" src="blob:https://sdi.sfda.gov.sa/84501c7f-a794-487b-b463-fe49d74f4c60" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>AA-&nbsp;Abiraterone&nbsp;Acetate</p><p>A planned interim analysis (IA) for OS was conducted after 333 deaths were observed. The study was unblinded based on the magnitude of clinical benefit observed and patients in the placebo group were offered treatment with Abiraterone Acetate. Overall survival was longer for&nbsp;Abiraterone&nbsp;Acetate&nbsp;than&nbsp;placebo with&nbsp;a&nbsp;25%&nbsp;reduction&nbsp;in&nbsp;riskof&nbsp;death&nbsp;(HR&nbsp;=&nbsp;0.752;&nbsp;95% CI: [0.606; 0.934], p = 0.0097), but OS was not mature and interim results did not meet the pre-specified stopping boundary for statistical significance (see Table 4). Survival continued to be followed after this IA.</p><p>The planned final analysis for OS was conducted after 741 deaths were observed (median follow up of 49 months). Sixtyfive percent (354 of 546) of patients treated with Abiraterone Acetate, compared with 71% (387 of 542) of patients treated with placebo, had died. A statistically significant OS benefit in favour of the Abiraterone Acetate-treated group was demonstrated&nbsp;with&nbsp;a&nbsp;19.4%&nbsp;reduction&nbsp;in&nbsp;risk&nbsp;of&nbsp;death&nbsp;(HR&nbsp;=&nbsp;0.806;&nbsp;95%&nbsp;CI:&nbsp;[0.697;&nbsp;0.931],&nbsp;p=&nbsp;0.0033)&nbsp;and&nbsp;an&nbsp;improvement&nbsp;in&nbsp;median&nbsp;OS&nbsp;of&nbsp;4.4&nbsp;months&nbsp;(Abiraterone&nbsp;Acetate&nbsp;34.7&nbsp;months, placebo 30.3 months) (see Table 6 and Figure 5). This improvement was demonstrated even though&nbsp;44%&nbsp;of&nbsp;patients&nbsp;in&nbsp;the&nbsp;placebo&nbsp;armreceived&nbsp;Abiraterone&nbsp;Acetate&nbsp;as&nbsp;subsequent&nbsp;therapy.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table&nbsp;6:&nbsp;Study&nbsp;302:&nbsp;Overall&nbsp;survival&nbsp;of&nbsp;patients&nbsp;treated&nbsp;with&nbsp;either&nbsp;Abiraterone Acetate&nbsp;or&nbsp;placebo&nbsp;in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone&nbsp;plus&nbsp;LHRH</strong></p><p><strong>analogues&nbsp;or&nbsp;prior&nbsp;orchiectomy</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Abiraterone&nbsp;Acetate</p><p>(N&nbsp;=&nbsp;546)</p></td><td style="vertical-align:top"><p>Placebo</p><p>(N&nbsp;=&nbsp;542)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Interim&nbsp;survival&nbsp;analysis</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Deaths&nbsp;(%)</p></td><td style="vertical-align:top"><p>147&nbsp;(27%)</p></td><td style="vertical-align:top"><p>186&nbsp;(34%)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;survival&nbsp;(months) (95% CI)</p></td><td style="vertical-align:top"><p>Not&nbsp;reached (NE; NE)</p></td><td style="vertical-align:top"><p>27.2</p><p>(25.95;&nbsp;NE)</p></td></tr><tr><td style="vertical-align:top"><p>p-value*</p></td><td colspan="2" style="vertical-align:top"><p>0.0097</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio**&nbsp;(95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.752&nbsp;(0.606;&nbsp;0.934)</p></td></tr><tr><td style="vertical-align:top"><p>Final&nbsp;survival&nbsp;analysis</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Deaths</p></td><td style="vertical-align:top"><p>354&nbsp;(65%)</p></td><td style="vertical-align:top"><p>387&nbsp;(71%)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;overall&nbsp;survival&nbsp;in months (95% CI)</p></td><td style="vertical-align:top"><p>34.7&nbsp;(32.7;&nbsp;36.8)</p></td><td style="vertical-align:top"><p>30.3&nbsp;(28.7;&nbsp;33.3)</p></td></tr><tr><td style="vertical-align:top"><p>p-value*</p></td><td colspan="2" style="vertical-align:top"><p>0.0033</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio**&nbsp;(95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.806&nbsp;(0.697;&nbsp;0.931)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>NE =&nbsp;Not&nbsp;Estimated</p><p>*&nbsp;p-value&nbsp;is&nbsp;derived&nbsp;from&nbsp;a&nbsp;log-rank&nbsp;test stratified&nbsp;by&nbsp;baseline&nbsp;ECOG&nbsp;score&nbsp;(0&nbsp;or&nbsp;1)</p><p>**&nbsp;Hazard&nbsp;ratio&nbsp;&lt;&nbsp;1&nbsp;favours&nbsp;Abiraterone&nbsp;Acetate</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Figure 5: Kaplan Meier survival curves of patients treated with either Abiraterone Acetate or placebo in combination with prednisone or prednisolone plus LHRH analogues or prior orchiectomy, final analysis</p><table cellpadding="0" cellspacing="0" align="left" style="width:369.25px"><tbody><tr><td style="width:1px">&nbsp;</td></tr><tr><td style="width:1px">&nbsp;</td><td style="width:368.75px"><img width="369" height="190" src="blob:https://sdi.sfda.gov.sa/c10d50ae-fbea-4f51-b7d3-9c0a9e142ce2" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>AA-&nbsp;Abiraterone&nbsp;Acetate</p><p>In addition to the observed improvements in overall survival and rPFS, benefit was demonstrated for Abiraterone Acetate vs. Placebo treatment in all secondary endpoint measures as follows:</p><p>Time&nbsp;to&nbsp;PSA&nbsp;progression&nbsp;based&nbsp;on&nbsp;PCWG2&nbsp;criteria:&nbsp;The&nbsp;median&nbsp;time&nbsp;to&nbsp;PSA&nbsp;progression&nbsp;was</p><p>11.1 months for patients receiving Abiraterone Acetate and 5.6 months for patients receiving placebo (HR =&nbsp;0.488;95% CI:&nbsp;[0.420;&nbsp;0.568], p &lt;&nbsp;0.0001).&nbsp;The time to&nbsp;PSA&nbsp;progression&nbsp;was approximately doubled with Abiraterone Acetate treatment (HR = 0.488). The proportion of subjects&nbsp;with&nbsp;a confirmed PSA&nbsp;response was&nbsp;greater in&nbsp;the Abiraterone Acetate group&nbsp;than in the&nbsp;placebo group&nbsp;(62%&nbsp;vs. 24%;&nbsp;p&nbsp;&lt;&nbsp;0.0001).&nbsp;In&nbsp;subjects&nbsp;with&nbsp;measurable&nbsp;soft tissue&nbsp;disease, significantly increased numbers of complete and partial tumor responses were seen with Abiraterone Acetate treatment.</p><p>Time to opiate use for cancer pain: The median time to opiate use for prostate cancer pain at the&nbsp;time&nbsp;of&nbsp;finalanalysis was&nbsp;33.4&nbsp;months for patients&nbsp;receiving&nbsp;Abiraterone&nbsp;Acetate&nbsp;and&nbsp;was</p><p>23.4&nbsp;months&nbsp;for&nbsp;patients&nbsp;receiving&nbsp;placebo (HR&nbsp;=&nbsp;0.721;&nbsp;95%&nbsp;CI:&nbsp;[0.614;&nbsp;0.846],&nbsp;p&nbsp;&lt;&nbsp;0.0001). Time to initiation of cytotoxic chemotherapy: The median time to initiation of cytotoxic chemotherapy was 25.2 months for patients receiving Abiraterone Acetate and 16.8 months for patients receiving placebo (HR = 0.580; 95% CI: [0.487; 0.691], p &lt; 0.0001).</p><p>Time to deterioration in ECOG performance score by &ge; 1 point: The median time to deterioration&nbsp;in&nbsp;ECOGperformance&nbsp;score&nbsp;by&nbsp;&ge;&nbsp;1&nbsp;point was&nbsp;12.3&nbsp;months&nbsp;for&nbsp;patients&nbsp;receiving Abiraterone Acetate and 10.9 months for patients receiving placebo (HR = 0.821; 95% CI: [0.714; 0.943], p = 0.0053).</p><p>The following&nbsp;study&nbsp;endpoints&nbsp;demonstrated&nbsp;a&nbsp;statistically&nbsp;significant advantage&nbsp;in&nbsp;favour&nbsp;of Abiraterone Acetate treatment:</p><p>Objective response: Objective response was defined as the proportion of subjects with measurable disease achieving a complete or partial response according to RECIST criteria (baseline lymph node size was required to be &ge; 2 cm to be considered a target lesion). The proportion&nbsp;of&nbsp;subjects&nbsp;with&nbsp;measurable&nbsp;disease&nbsp;at&nbsp;baseline&nbsp;who had&nbsp;anobjective&nbsp;response&nbsp;was 36% in the Abiraterone Acetate group and 16% in the placebo group (p &lt; 0.0001).</p><p>Pain: Treatment with Abiraterone Acetate significantly reduced the risk of average pain intensity&nbsp;progression&nbsp;by18%&nbsp;compared&nbsp;with&nbsp;placebo&nbsp;(p&nbsp;=&nbsp;0.0490).&nbsp;The&nbsp;median&nbsp;time&nbsp;to&nbsp;progression&nbsp;was&nbsp;26.7&nbsp;months&nbsp;in&nbsp;the&nbsp;Abiraterone&nbsp;Acetate&nbsp;group&nbsp;and&nbsp;18.4&nbsp;months&nbsp;in&nbsp;the&nbsp;placebo&nbsp;group.</p><p>Time to degradation in the FACT-P (Total Score): Treatment with Abiraterone Acetate decreased the risk of&nbsp;FACT-P (Total&nbsp;Score) degradation&nbsp;by&nbsp;22% compared with&nbsp;placebo (p = 0.0028). The median time to degradation in FACT-P (Total Score) was 12.7 months in the Abiraterone Acetate group and 8.3 months in the placebo group.</p><p>Study&nbsp;301 (patients&nbsp;who&nbsp;had&nbsp;received prior&nbsp;chemotherapy)</p><p>Study 301 enrolled patients who had received prior docetaxel. Patients were not required to show disease progression on docetaxel, as toxicity from this chemotherapy may have led to&nbsp;discontinuation.</p><p>Patients&nbsp;were&nbsp;maintained&nbsp;on&nbsp;study&nbsp;treatments&nbsp;until&nbsp;there&nbsp;was&nbsp;PSA&nbsp;progression&nbsp;(confirmed&nbsp;25% increase over the patient&#39;s baseline/nadir) together with protocol-defined radiographic progression and symptomatic or clinical progression. Patients with prior ketoconazole treatment for prostate cancer were excluded from this study. The primary efficacy endpoint was overall survival.</p><p>The&nbsp;median&nbsp;age&nbsp;of&nbsp;enrolled&nbsp;patients&nbsp;was&nbsp;69&nbsp;years&nbsp;(range&nbsp;39-95).&nbsp;The&nbsp;number&nbsp;of&nbsp;patients&nbsp;treated with&nbsp;AbirateroneAcetate&nbsp;by&nbsp;racial&nbsp;group&nbsp;was&nbsp;Caucasian&nbsp;737&nbsp;(93.2%),&nbsp;Black&nbsp;28&nbsp;(3.5%),&nbsp;Asian 11&nbsp;(1.4%)&nbsp;and&nbsp;other&nbsp;14&nbsp;(1.8%).&nbsp;Elevenpercent&nbsp;of&nbsp;patients&nbsp;enrolled&nbsp;had&nbsp;an&nbsp;ECOG&nbsp;performance score of 2; 70% had radiographic evidence of disease progression with or without PSA progression;&nbsp;70%&nbsp;had&nbsp;received&nbsp;one&nbsp;prior&nbsp;cytotoxic&nbsp;chemotherapy&nbsp;and&nbsp;30%&nbsp;receivedtwo.&nbsp;Liver metastasis was present in 11% of patients treated with Abiraterone Acetate.</p><p>In&nbsp;a&nbsp;planned&nbsp;analysis&nbsp;conducted&nbsp;after 552&nbsp;deaths&nbsp;were&nbsp;observed, 42% (333&nbsp;of&nbsp;797) of&nbsp;patients treated with Abiraterone Acetate compared with 55% (219 of 398) of patients treated with placebo,&nbsp;had&nbsp;died.&nbsp;A&nbsp;statisticallysignificant&nbsp;improvement in&nbsp;median&nbsp;overall&nbsp;survival&nbsp;was&nbsp;seen in patients treated with Abiraterone Acetate (see Table 7).</p><table border="1" cellspacing="0" cellpadding="0" style="width:1340px"><tbody><tr><td colspan="3" style="vertical-align:top; width:1337px"><p><strong>Table</strong><strong>&nbsp;</strong><strong>7:</strong><strong>&nbsp;</strong><strong>Overall</strong><strong>&nbsp;</strong><strong>survival</strong><strong>&nbsp;</strong><strong>of</strong><strong>&nbsp;</strong><strong>patients</strong><strong>&nbsp;</strong><strong>treated</strong><strong>&nbsp;</strong><strong>with</strong><strong>&nbsp;</strong><strong>either</strong><strong>&nbsp;</strong><strong>Abiraterone</strong><strong>&nbsp;</strong><strong>Acetate</strong><strong>&nbsp;</strong><strong>or</strong><strong>placebo</strong></p><p><strong>in&nbsp;combination&nbsp;with&nbsp;prednisone&nbsp;or&nbsp;prednisolone&nbsp;plus&nbsp;LHRH&nbsp;analogues&nbsp;or&nbsp;priororchiectomy</strong></p></td></tr><tr><td style="vertical-align:top; width:680px"><p>&nbsp;</p></td><td style="vertical-align:top; width:337px"><p>Abiraterone&nbsp;Acetate (N = 797)</p></td><td style="vertical-align:top; width:322px"><p>Placebo&nbsp;(N&nbsp;=&nbsp;398)</p></td></tr><tr><td style="vertical-align:top; width:680px"><p><strong>Primary&nbsp;Survival&nbsp;Analysis</strong></p></td><td colspan="2" style="vertical-align:top; width:659px"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:680px"><p>Deaths&nbsp;(%)</p></td><td style="vertical-align:top; width:337px"><p>333(42%)</p></td><td style="vertical-align:top; width:322px"><p>219&nbsp;(55&nbsp;%)</p></td></tr><tr><td style="vertical-align:top; width:680px"><p>Median&nbsp;survival&nbsp;(months)&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top; width:337px"><p>14.8&nbsp;(14.1;&nbsp;15.4)</p></td><td style="vertical-align:top; width:322px"><p>10.9&nbsp;(10.2;12.0)</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>p-value<sup>a</sup></p></td><td colspan="2" style="vertical-align:top"><p>&lt;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio&nbsp;(95%&nbsp;CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.646&nbsp;(0.543&nbsp;;&nbsp;0.768)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Updated&nbsp;Survival&nbsp;Analysis</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Deaths&nbsp;(%)</p></td><td style="vertical-align:top"><p>501&nbsp;(63&nbsp;%)</p></td><td style="vertical-align:top"><p>274&nbsp;(69&nbsp;%)</p></td></tr><tr><td style="vertical-align:top"><p>Median&nbsp;survival&nbsp;(months)&nbsp;(95%&nbsp;CI)</p></td><td style="vertical-align:top"><p>15.8&nbsp;(14.8;&nbsp;17.0)</p></td><td style="vertical-align:top"><p>11.2&nbsp;(10.4;&nbsp;13.1)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard&nbsp;ratio&nbsp;(95%&nbsp;CI)<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.740&nbsp;(0.638;&nbsp;0.859)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>a</sup>p-value is derived from a log-rank test stratified by ECOG performance status score (0-1 vs.&nbsp;2),&nbsp;pain&nbsp;score&nbsp;(absent&nbsp;vs.&nbsp;present),&nbsp;number&nbsp;of&nbsp;prior&nbsp;chemotherapy&nbsp;regimens&nbsp;(1&nbsp;vs.&nbsp;2),&nbsp;and type of disease progression (PSA only vs. radiographic).</p><p><sup>b</sup>Hazard ratio is derived from a stratified proportional hazards model. Hazard ratio &lt; 1 favours Abiraterone Acetate</p></td></tr></tbody></table><p>&nbsp;</p><p>At all&nbsp;evaluation time points after the initial few months of treatment, a higher proportion of patients treated with Abiraterone Acetate remained alive, compared with the proportion of patients treated with placebo (see Figure 6).</p><p>&nbsp;</p><p>Figure 6: Kaplan Meier survival curves of patients treated with either Abiraterone Acetate or placebo in combination with prednisone or prednisolone plus LHRH analogues or prior orchiectomy</p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="366" height="234" src="blob:https://sdi.sfda.gov.sa/a636e47d-f888-4b00-b366-2e4de571ab2a" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>AA-&nbsp;Abiraterone&nbsp;Acetate</p><p>Subgroup survival analyses showed a consistent survival benefit for treatment with Abiraterone Acetate (see Figure 7).</p><p>&nbsp;</p><p>Figure&nbsp;7:&nbsp;Overall&nbsp;survival&nbsp;by&nbsp;subgroup:&nbsp;hazard&nbsp;ratio&nbsp;and&nbsp;95% confidence&nbsp;interval</p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="378" height="216" src="blob:https://sdi.sfda.gov.sa/49cb9bee-93b9-49c6-bdef-a2161c78c812" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>AA = Abiraterone Acetate; BPI = Brief Pain Inventory; C.I. = confidence interval; ECOG = Eastern Cooperative Oncology Group performance score; HR = hazard ratio; NE = not evaluable.</p><p>&nbsp;</p><p>In addition to the observed improvement in overall survival, all secondary study endpoints favoured Abiraterone Acetate and were statistically significant after adjusting for multiple testing as follows:</p><p>Patients&nbsp;receiving&nbsp;Abiraterone&nbsp;Acetate&nbsp;demonstrated&nbsp;a&nbsp;significantly&nbsp;higher&nbsp;total&nbsp;PSA&nbsp;response rate&nbsp;(defined as a &ge; 50% reduction from&nbsp;baseline), compared with&nbsp;patients receiving placebo, 38% vs. 10%, p &lt; 0.0001.</p><p>The median time to PSA progression was 10.2 months for patients treated with Abiraterone Acetate&nbsp;and&nbsp;6.6&nbsp;monthsfor&nbsp;patients&nbsp;treated&nbsp;with&nbsp;placebo&nbsp;(HR&nbsp;=&nbsp;0.580;&nbsp;95%&nbsp;CI:&nbsp;[0.462;&nbsp;0.728],&nbsp;p &lt;&nbsp;0.0001).</p><p>The median radiographic progression-free survival was 5.6 months for patients treated with Abiraterone&nbsp;Acetateand&nbsp;3.6&nbsp;months for patients&nbsp;who received&nbsp;placebo (HR&nbsp;=&nbsp;0.673;&nbsp;95% CI: [0.585; 0.776], p &lt; 0.0001).</p><p><u>Pain</u></p><p>The proportion of patients with pain palliation was statistically significantly higher in the Abiraterone&nbsp;Acetategroup&nbsp;than&nbsp;in&nbsp;the&nbsp;placebo group&nbsp;(44%&nbsp;vs. 27%,&nbsp;p&nbsp;=&nbsp;0.0002).&nbsp;A responder for pain palliation was defined as a patient who experienced at least a 30% reduction from baseline in the BPI-SF worst pain intensity score over the last 24 hours without any increase in analgesic usage score observed at two consecutive evaluations four weeks apart. Only patients with a baseline pain score of &ge; 4 and at least one post-baseline pain score were analysed (N = 512) for pain palliation.</p><p>A lower proportion of patients treated with Abiraterone Acetate had pain progression compared to patients taking placebo at 6 (22% vs. 28%), 12 (30% vs. 38%) and 18 months (35% vs. 46%). Pain progression was defined as an increase from baseline of &ge; 30% in the BPI-SF worst pain intensity score&nbsp;over the previous 24 hours without a decrease in&nbsp;analgesic usage score observed at two consecutive visits, or an increase of &ge; 30% in analgesic usage&nbsp;score observed at two consecutive visits. The time to pain progression at the 25th percentile was 7.4 months in the Abiraterone Acetate group, versus 4.7 months in the placebo group.</p><p><u>Skeletal-related&nbsp;events</u></p><p>A lower proportion of patients in the Abiraterone Acetate group had skeletal-related events compared&nbsp;with&nbsp;theplacebo group&nbsp;at&nbsp;6&nbsp;months&nbsp;(18% vs. 28%), 12&nbsp;months&nbsp;(30% vs. 40%), and 18 months&nbsp;(35% vs. 40%).&nbsp;The time&nbsp;to first skeletal-related event at&nbsp;the&nbsp;25th&nbsp;percentile in&nbsp;the Abiraterone&nbsp;Acetate&nbsp;group&nbsp;was&nbsp;twice&nbsp;that&nbsp;of&nbsp;the&nbsp;control&nbsp;groupat&nbsp;9.9&nbsp;months&nbsp;versus&nbsp;4.9&nbsp;months. A skeletal-related event was defined as a pathological fracture, spinal cord compression, palliative radiation to bone, or surgery to bone.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Following administration of abiraterone acetate, the pharmacokinetics of abiraterone and abiraterone acetate have been studied in healthy subjects, patients with metastatic advanced prostate cancer and subjects without cancer with hepatic or renal impairment. Abiraterone acetate is rapidly converted&nbsp;<em>in vivo&nbsp;</em>to abiraterone, an androgen biosynthesis inhibitor (see section 5.1).</p><p><strong><u>Absorption</u></strong></p><p>Following oral administration of abiraterone acetate in the fasting state, the time to reach maximum plasma abiraterone concentration is approximately 2 hours.</p><p>Administration&nbsp;of&nbsp;abiraterone&nbsp;acetate&nbsp;with&nbsp;food,&nbsp;compared&nbsp;with&nbsp;administration&nbsp;in&nbsp;a&nbsp;fasted&nbsp;state, results in up to a 10-fold (AUC) and up to a 17-fold (Cmax) increase in mean systemic exposure&nbsp;of&nbsp;abiraterone, depending&nbsp;on&nbsp;the fat content of&nbsp;the meal. Given&nbsp;the normal&nbsp;variation in the content and composition of meals, taking Abiraterone Acetate with meals has the potential to result in highly variable exposures. Therefore, Abiraterone Acetate must not be taken&nbsp;with&nbsp;food. It&nbsp;should&nbsp;be&nbsp;taken&nbsp;at least two&nbsp;hours&nbsp;after&nbsp;eating&nbsp;and&nbsp;no food&nbsp;should&nbsp;be&nbsp;eaten for&nbsp;at least onehour&nbsp;after&nbsp;taking Abiraterone&nbsp;Acetate.&nbsp;The&nbsp;tablets&nbsp;should be&nbsp;swallowed whole with water (see section 4.2).</p><p><strong><u>Distribution</u></strong></p><p>The plasma protein binding of 14C-abiraterone in human plasma is 99.8%. The apparent volume of distribution is approximately 5,630 l, suggesting that abiraterone extensively distributes to peripheral tissues.</p><p><strong><u>Biotransformation</u></strong></p><p>Following oral administration of 14C-abiraterone acetate as capsules, abiraterone acetate is hydrolysed to abiraterone, which then undergoes metabolism including sulphation, hydroxylation and oxidation primarily in the liver. The majority of circulating radioactivity (approximately 92%) is found in the form of metabolites of abiraterone. Of 15 detectable metabolites, 2 main metabolites, abiraterone sulphate&nbsp;and N-oxide abiraterone sulphate, each represents approximately 43% of total radioactivity.</p><p><strong><u>Elimination</u></strong></p><p>The mean half-life of abiraterone in plasma is approximately 15 hours based on data from healthy subjects. Following oral administration of&nbsp;<sup>14</sup>C-abiraterone acetate 1,000 mg, approximately 88% of the radioactive dose is recovered in faeces and approximately 5% in urine. The major compounds present in faeces are unchanged abiraterone acetate and abiraterone (approximately 55% and 22% of the administered dose, respectively).</p><p><strong><u>Hepatic&nbsp;impairment</u></strong></p><p>The pharmacokinetics of&nbsp;abiraterone acetate was examined in&nbsp;subjects with&nbsp;pre-existing mild or moderate hepatic impairment (Child-Pugh Class A and B, respectively) and in healthy control&nbsp;subjects. Systemic&nbsp;exposure&nbsp;to abiraterone&nbsp;after&nbsp;a&nbsp;single&nbsp;oral&nbsp;1,000 mg&nbsp;dose&nbsp;increased by approximately 11% and 260% in subjects with mild and moderate preexisting hepatic impairment, respectively. The mean half-life of&nbsp;abiraterone is prolonged to approximately&nbsp;18 hours&nbsp;in&nbsp;subjects&nbsp;with&nbsp;mild&nbsp;hepatic&nbsp;impairment&nbsp;and&nbsp;to&nbsp;approximately&nbsp;19&nbsp;hours&nbsp;in&nbsp;subjects&nbsp;with moderate hepatic impairment.</p><p>In another trial, the pharmacokinetics of abiraterone were examined in subjects with pre- existing severe (n = 8) hepatic impairment (Child-Pugh Class C) and in 8 healthy control subjects with normal hepatic function. The AUC to abiraterone increased by approximately 600% and the fraction of free drug increased by 80% in subjects with severe hepatic impairment compared to subjects with normal hepatic function.</p><p>No dose adjustment is necessary for patients with pre-existing mild hepatic impairment. The use of abiraterone acetate should be cautiously assessed in patients with moderate hepatic impairment&nbsp;in&nbsp;whom&nbsp;the&nbsp;benefit&nbsp;clearlyshould&nbsp;outweigh&nbsp;the&nbsp;possible&nbsp;risk&nbsp;(see&nbsp;sections&nbsp;4.2&nbsp;and 4.4). abiraterone acetate should not be used in patients with severe hepatic impairment (see sections4.2, 4.3 and 4.4).</p><p>For patients who develop hepatotoxicity during treatment, suspension of treatment and dose adjustment may be required (see sections 4.2 and 4.4).</p><p><strong><u>Renal&nbsp;impairment</u></strong></p><p>The pharmacokinetics of abiraterone acetate was compared in patients with end-stage renal disease&nbsp;on&nbsp;a&nbsp;stablehaemodialysis&nbsp;schedule&nbsp;versus matched control&nbsp;subjects&nbsp;with&nbsp;normal&nbsp;renal function. Systemic exposure to abiraterone after a&nbsp;single oral&nbsp;1,000 mg dose did not increase in subjects with end-stage renal disease on dialysis. Administration in patients with renal impairment, including severe renal impairment, does not require dose reduction (see section 4.2).&nbsp;However,&nbsp;there&nbsp;is&nbsp;no clinical&nbsp;experience in&nbsp;patients&nbsp;with&nbsp;prostate&nbsp;cancer&nbsp;and&nbsp;severe&nbsp;renal impairment. Caution is advised in these patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In all animal toxicity studies, circulating testosterone levels were significantly reduced. As a result, reduction in organ weights and morphological&nbsp;and/or histopathological&nbsp;changes in the reproductive organs, and the adrenal, pituitary and mammary glands were observed. All changes&nbsp;showed complete&nbsp;or&nbsp;partial&nbsp;reversibility. The changes inthe reproductive organs and androgen-sensitive&nbsp;organs&nbsp;are&nbsp;consistent with&nbsp;the&nbsp;pharmacology&nbsp;of&nbsp;abiraterone.&nbsp;Alltreatment- related hormonal changes reversed or were shown to be resolving after a 4-week recovery&nbsp;period.</p><p>In fertility studies in both male and female rats, abiraterone acetate reduced fertility, which was completely reversible in 4 to 16 weeks after abiraterone acetate was stopped.</p><p>In a developmental&nbsp;toxicity study in the rat, abiraterone acetate affected pregnancy including reduced foetal weight and survival. Effects on the external genitalia were observed though abiraterone acetate was not teratogenic.</p><p>In&nbsp;these fertility&nbsp;and&nbsp;developmental&nbsp;toxicity&nbsp;studies performed in&nbsp;the&nbsp;rat,&nbsp;all&nbsp;effects&nbsp;were&nbsp;related&nbsp;to the pharmacological activity of abiraterone.</p><p>Aside&nbsp;from&nbsp;reproductive&nbsp;organ&nbsp;changes&nbsp;seen&nbsp;in&nbsp;all&nbsp;animal&nbsp;toxicology&nbsp;studies,&nbsp;non-clinical&nbsp;data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Abiraterone acetate was not carcinogenic in a 6-month study in the transgenic (Tg.rasH2) mouse. In a 24- month&nbsp;carcinogenicity study in the rat, abiraterone acetate increased the incidence of interstitial&nbsp;cell neoplasms in the testes. This finding is considered related to the pharmacological action of abiraterone and rat specific. Abiraterone acetate was not carcinogenic in female rats.</p><p>The&nbsp;active&nbsp;substance,&nbsp;abiraterone,&nbsp;shows&nbsp;an&nbsp;environmental&nbsp;risk for&nbsp;the&nbsp;aquatic&nbsp;environment, especially to fish.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p><p>Microcrystalline&nbsp;cellulose&nbsp;PH&nbsp;101</p><p>Croscarmellose sodium</p><p>Povidone K 30&nbsp;</p><p>Sodium&nbsp;laurylsulfate</p><p>Colloidal&nbsp;silicon&nbsp;dioxide</p><p>Magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do&nbsp;not&nbsp;store&nbsp;above&nbsp;30&ordm;C.&nbsp;Keep&nbsp;out of&nbsp;the&nbsp;sight&nbsp;and&nbsp;reach&nbsp;of&nbsp;children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BIRATO&nbsp;tablets&nbsp;are&nbsp;white&nbsp;to&nbsp;off-white,&nbsp;oval&nbsp;shaped&nbsp;tablets,&nbsp;debossed&nbsp;with&nbsp;&ldquo;ABR&rdquo;&nbsp;on&nbsp;one&nbsp;side and &ldquo;250&quot; on other side. 120 tablets of BIRATO are packed in HDPE container and closed&nbsp;with CR closure with induction sealing wad.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on its mechanism of action, this medicinal product may harm a developing foetus; therefore,&nbsp;women&nbsp;who&nbsp;arepregnant&nbsp;or&nbsp;may&nbsp;be&nbsp;pregnant&nbsp;should&nbsp;not&nbsp;handle&nbsp;it&nbsp;without&nbsp;protection, e.g., gloves.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. This medicinal product may pose a risk to the aquatic environment (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tadawi Biomedical Company, 
Sudair Industrial Zone, 
Sudair,
Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                07/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>